<!DOCTYPE html>
<html lang="en" class="grade-c">
<head>
    <title>Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma | Leukemia</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/leu.rss"/>


    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin>

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480" />

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"haematological-cancer;pre-clinical-studies","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Leukemia","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41375-024-02401-9"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Brandon S. Willis","Kevin Mongeon","Hannah Dry","India L. Neveras","Nadezda Bryan","Meghana Pandya","Justine Roderick-Richardson","Wendan Xu","Li Yang","Alan Rosen","Corinne Reimer","Liliana Tuskova","Pavel Klener","Jerome T. Mettetal","Georg Lenz","Simon T. Barry"],"publishedAt":1726444800,"publishedAtString":"2024-09-16","title":"Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Haematological cancer,Preclinical research"},"journal":{"pcode":"leu","title":"leukemia","volume":"38","issue":"12","id":41375,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"US","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-card--major .c-card__title,.u-h1,.u-h2,h1,h2{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h3,h4,h5,h6{letter-spacing:-.0117156rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}.c-card--major .c-card__title,.u-h1,.u-h2,button,h1,h2{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}button{border-radius:0;cursor:pointer}.c-card--major .c-card__title,.u-h1,.u-h2,h1,h2{font-weight:700}h1{font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,h2{font-size:1.5rem;letter-spacing:-.0117156rem;line-height:1.6rem}.u-h3{letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h3,h4,h5,h6{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:700;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-reading-companion__figure-title,.u-h4,h3,h4,h5,h6{letter-spacing:-.0117156rem}.c-reading-companion__figure-title,.u-h4{font-size:1.125rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;padding:0}.c-article-identifiers__item{list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #fff;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#0067c5;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.app-researcher-popup__link.hover,.app-researcher-popup__link.visited,.app-researcher-popup__link:hover,.app-researcher-popup__link:visited,.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-authors-search__list{align-items:center;display:flex;flex-wrap:wrap;gap:16px 16px;justify-content:center}@media only screen and (min-width:320px){.c-article-authors-search__list{justify-content:normal}}.c-article-authors-search__text{align-items:center;display:flex;flex-flow:column wrap;font-size:14px;justify-content:center}@media only screen and (min-width:320px){.c-article-authors-search__text{flex-direction:row;font-size:16px}}.c-article-authors-search__links-text{font-weight:700;margin-right:8px;text-align:center}@media only screen and (min-width:320px){.c-article-authors-search__links-text{text-align:left}}.c-article-authors-search__list-item--left{flex:1 1 100%}@media only screen and (min-width:320px){.c-article-authors-search__list-item--left{flex-basis:auto}}.c-article-authors-search__list-item--right{flex:1 1 auto}.c-article-identifiers{margin:0}.c-article-identifiers__item{border-right:2px solid #cedbe0;color:#222;font-size:14px}@media only screen and (min-width:320px){.c-article-identifiers__item{font-size:16px}}.c-article-identifiers__item:last-child{border-right:none}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.app-author-list{color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;line-height:1.4;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-weight:400;line-height:1.5;margin-bottom:4px}.c-ad__label,.c-meta{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem}.c-meta{color:inherit;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-link-inherit{color:inherit}.u-list-reset{list-style:none;margin:0;padding:0}.u-sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.u-text-bold{font-weight:700}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-2882bcd053.css" media="print" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-2882bcd053.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href=/static/images/favicons/nature/apple-touch-icon-f39cb19454.png>
<link rel="icon" type="image/png" sizes="48x48" href=/static/images/favicons/nature/favicon-48x48-b52890008c.png>
<link rel="icon" type="image/png" sizes="32x32" href=/static/images/favicons/nature/favicon-32x32-3fe59ece92.png>
<link rel="icon" type="image/png" sizes="16x16" href=/static/images/favicons/nature/favicon-16x16-951651ab72.png>
<link rel="manifest" href=/static/manifest.json crossorigin="use-credentials">
<link rel="mask-icon" href=/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg color="#000000">
<link rel="shortcut icon" href=/static/images/favicons/nature/favicon.ico>
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content=/static/browserconfig.xml>
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://sgtm.nature.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-19e70d4396.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-f7c78bebb9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-160f9548b6.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-5df2fdd53b.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma","description":"The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-α/δ inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL PTEN wildtype cell lines and those harbouring PTEN mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL.","datePublished":"2024-09-16T00:00:00Z","dateModified":"2024-09-16T00:00:00Z","pageStart":"2663","pageEnd":"2674","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41375-024-02401-9","keywords":["Haematological cancer","Preclinical research","Medicine/Public Health","general","Internal Medicine","Intensive / Critical Care Medicine","Cancer Research","Oncology","Hematology"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig4_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig5_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig6_HTML.png"],"isPartOf":{"name":"Leukemia","issn":["1476-5551","0887-6924"],"volumeNumber":"38","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group UK","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Brandon S. Willis","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Kevin Mongeon","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Hannah Dry","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"India L. Neveras","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Nadezda Bryan","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Meghana Pandya","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Justine Roderick-Richardson","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Wendan Xu","affiliation":[{"name":"University Hospital Münster","address":{"name":"Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Li Yang","affiliation":[{"name":"University Hospital Münster","address":{"name":"Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Alan Rosen","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Corinne Reimer","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Liliana Tuskova","affiliation":[{"name":"Charles University Prague","address":{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Pavel Klener","affiliation":[{"name":"Charles University Prague","address":{"name":"Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jerome T. Mettetal","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Boston, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Georg Lenz","url":"http://orcid.org/0000-0002-4728-1693","affiliation":[{"name":"University Hospital Münster","address":{"name":"Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Simon T. Barry","url":"http://orcid.org/0000-0002-8511-0588","affiliation":[{"name":"AstraZeneca","address":{"name":"Bioscience, Early Oncology, AstraZeneca, Cambridge, UK","@type":"PostalAddress"},"@type":"Organization"}],"email":"simon.t.barry@astrazeneca.com","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41375-024-02401-9">
    
    
    <meta name="journal_id" content="41375"/>
    <meta name="dc.title" content="Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma"/>
    <meta name="dc.source" content="Leukemia 2024 38:12"/>
    <meta name="dc.format" content="text/html"/>
    <meta name="dc.publisher" content="Nature Publishing Group"/>
    <meta name="dc.date" content="2024-09-16"/>
    <meta name="dc.type" content="OriginalPaper"/>
    <meta name="dc.language" content="En"/>
    <meta name="dc.copyright" content="2024 The Author(s)"/>
    <meta name="dc.rights" content="2024 The Author(s)"/>
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com"/>
    <meta name="dc.description" content="The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-&#945;/&#948; inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL PTEN wildtype cell lines and those harbouring PTEN mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL."/>
    <meta name="prism.issn" content="1476-5551"/>
    <meta name="prism.publicationName" content="Leukemia"/>
    <meta name="prism.publicationDate" content="2024-09-16"/>
    <meta name="prism.volume" content="38"/>
    <meta name="prism.number" content="12"/>
    <meta name="prism.section" content="OriginalPaper"/>
    <meta name="prism.startingPage" content="2663"/>
    <meta name="prism.endingPage" content="2674"/>
    <meta name="prism.copyright" content="2024 The Author(s)"/>
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com"/>
    <meta name="prism.url" content="https://www.nature.com/articles/s41375-024-02401-9"/>
    <meta name="prism.doi" content="doi:10.1038/s41375-024-02401-9"/>
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41375-024-02401-9.pdf"/>
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41375-024-02401-9"/>
    <meta name="citation_journal_title" content="Leukemia"/>
    <meta name="citation_journal_abbrev" content="Leukemia"/>
    <meta name="citation_publisher" content="Nature Publishing Group"/>
    <meta name="citation_issn" content="1476-5551"/>
    <meta name="citation_title" content="Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma"/>
    <meta name="citation_volume" content="38"/>
    <meta name="citation_issue" content="12"/>
    <meta name="citation_publication_date" content="2024/12"/>
    <meta name="citation_online_date" content="2024/09/16"/>
    <meta name="citation_firstpage" content="2663"/>
    <meta name="citation_lastpage" content="2674"/>
    <meta name="citation_article_type" content="Article"/>
    <meta name="citation_fulltext_world_readable" content=""/>
    <meta name="citation_language" content="en"/>
    <meta name="dc.identifier" content="doi:10.1038/s41375-024-02401-9"/>
    <meta name="DOI" content="10.1038/s41375-024-02401-9"/>
    <meta name="size" content="213778"/>
    <meta name="citation_doi" content="10.1038/s41375-024-02401-9"/>
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41375-024-02401-9&amp;api_key="/>
    <meta name="description" content="The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-&#945;/&#948; inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL PTEN wildtype cell lines and those harbouring PTEN mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL."/>
    <meta name="dc.creator" content="Willis, Brandon S."/>
    <meta name="dc.creator" content="Mongeon, Kevin"/>
    <meta name="dc.creator" content="Dry, Hannah"/>
    <meta name="dc.creator" content="Neveras, India L."/>
    <meta name="dc.creator" content="Bryan, Nadezda"/>
    <meta name="dc.creator" content="Pandya, Meghana"/>
    <meta name="dc.creator" content="Roderick-Richardson, Justine"/>
    <meta name="dc.creator" content="Xu, Wendan"/>
    <meta name="dc.creator" content="Yang, Li"/>
    <meta name="dc.creator" content="Rosen, Alan"/>
    <meta name="dc.creator" content="Reimer, Corinne"/>
    <meta name="dc.creator" content="Tuskova, Liliana"/>
    <meta name="dc.creator" content="Klener, Pavel"/>
    <meta name="dc.creator" content="Mettetal, Jerome T."/>
    <meta name="dc.creator" content="Lenz, Georg"/>
    <meta name="dc.creator" content="Barry, Simon T."/>
    <meta name="dc.subject" content="Haematological cancer"/>
    <meta name="dc.subject" content="Preclinical research"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms; citation_author=SH Swerdlow, E Campo, SA Pileri, NL Harris, H Stein, R Siebert; citation_volume=127; citation_publication_date=2016; citation_pages=2375-90; citation_id=CR1"/>
    <meta name="citation_reference" content="citation_journal_title=Cancer Cell; citation_title=A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications; citation_author=GW Wright, DW Huang, JD Phelan, ZA Coulibaly, S Roulland, RM Young; citation_volume=37; citation_publication_date=2020; citation_pages=551-68.e14; citation_id=CR2"/>
    <meta name="citation_reference" content="citation_journal_title=Cancer J; citation_title=Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma; citation_author=M Roschewski, JD Phelan, WH Wilson; citation_volume=26; citation_publication_date=2020; citation_pages=195-205; citation_id=CR3"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl J Med; citation_title=Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma; citation_author=H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trneny, JP Sharman; citation_volume=386; citation_publication_date=2022; citation_pages=351-63; citation_id=CR4"/>
    <meta name="citation_reference" content="citation_journal_title=Am J Pathol; citation_title=AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma; citation_author=J Wang, ZY Xu-Monette, KJ Jabbar, Q Shen, GC Manyam, A Tzankov; citation_volume=187; citation_publication_date=2017; citation_pages=1700-16; citation_id=CR5"/>
    <meta name="citation_reference" content="citation_journal_title=Cell Cycle; citation_title=PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma; citation_author=M Pfeifer, G Lenz; citation_volume=12; citation_publication_date=2013; citation_pages=3347-8; citation_id=CR6"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL; citation_author=T Erdmann, P Klener, JT Lynch, M Grau, P Vo&#269;kov&#225;, J Molinsky; citation_volume=130; citation_publication_date=2017; citation_pages=310-22; citation_id=CR7"/>
    <meta name="citation_reference" content="citation_journal_title=Oncotarget; citation_title=PI3K&#948; inhibition causes feedback activation of PI3K&#945; in the ABC subtype of diffuse large B-cell lymphoma; citation_author=GN Pongas, CM Annunziata, LM Staudt; citation_volume=8; citation_publication_date=2017; citation_pages=81794-802; citation_id=CR8"/>
    <meta name="citation_reference" content="citation_journal_title=Cancer Cell; citation_title=SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas; citation_author=L Chen, S Monti, P Juszczynski, J Ouyang, B Chapuy, D Neuberg; citation_volume=23; citation_publication_date=2013; citation_pages=826-38; citation_id=CR9"/>
    <meta name="citation_reference" content="citation_journal_title=Ann Oncol; citation_title=Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma; citation_author=M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, SE Assouline; citation_volume=28; citation_publication_date=2017; citation_pages=2169-78; citation_id=CR10"/>
    <meta name="citation_reference" content="citation_journal_title=Leukemia; citation_title=Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma; citation_author=G Lenz, E Hawkes, G Verhoef, C Haioun, S Thye Lim, D Seog Heo; citation_volume=34; citation_publication_date=2020; citation_pages=2184-97; citation_id=CR11"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl J Med; citation_title=Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer; citation_author=NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno; citation_volume=388; citation_publication_date=2023; citation_pages=2058-70; citation_id=CR12"/>
    <meta name="citation_reference" content="citation_journal_title=Oncotarget; citation_title=Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma; citation_author=SA Ezell, S Wang, T Bihani, Z Lai, SE Grosskurth, S Tepsuporn; citation_volume=7; citation_publication_date=2016; citation_pages=9163-74; citation_id=CR13"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma; citation_author=W Xu, P Berning, G Lenz; citation_volume=138; citation_publication_date=2021; citation_pages=1110-9; citation_id=CR14"/>
    <meta name="citation_reference" content="citation_journal_title=Trends Cancer; citation_title=Targeting BCL-2-like Proteins to Kill Cancer Cells; citation_author=S Cory, AW Roberts, PM Colman, JM Adams; citation_volume=2; citation_publication_date=2016; citation_pages=443-60; citation_id=CR15"/>
    <meta name="citation_reference" content="citation_journal_title=N. Engl J Med; citation_title=Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia; citation_author=CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei; citation_volume=383; citation_publication_date=2020; citation_pages=617-29; citation_id=CR16"/>
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol; citation_title=Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study; citation_author=S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir; citation_volume=17; citation_publication_date=2016; citation_pages=768-78; citation_id=CR17"/>
    <meta name="citation_reference" content="citation_journal_title=Blood Adv; citation_title=Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes; citation_author=H Scholze, RE Stephenson, R Reynolds, S Shah, R Puri, SD Butler; citation_volume=4; citation_publication_date=2020; citation_pages=5226-31; citation_id=CR18"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma; citation_author=F Morschhauser, P Feugier, IW Flinn, R Gasiorowski, R Greil, A Illes; citation_volume=137; citation_publication_date=2021; citation_pages=600-9; citation_id=CR19"/>
    <meta name="citation_reference" content="citation_journal_title=Cell Death Dis; citation_title=MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies; citation_author=GS Choudhary, S Al-Harbi, S Mazumder, BT Hill, MR Smith, J Bodo; citation_volume=6; citation_publication_date=2015; citation_id=CR20"/>
    <meta name="citation_reference" content="citation_journal_title=Mol Cancer Ther; citation_title=ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo; citation_author=S Ackler, Y Xiao, MJ Mitten, K Foster, A Oleksijew, M Refici; citation_volume=7; citation_publication_date=2008; citation_pages=3265-74; citation_id=CR21"/>
    <meta name="citation_reference" content="citation_journal_title=Cancer Res; citation_title=Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition; citation_author=JL Coloff, AN Macintyre, AG Nichols, T Liu, CA Gallo, DR Plas; citation_volume=71; citation_publication_date=2011; citation_pages=5204-13; citation_id=CR22"/>
    <meta name="citation_reference" content="citation_journal_title=Oncotarget; citation_title=MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma; citation_author=JS Lee, SS Tang, V Ortiz, TT Vo, DA Fruman; citation_volume=6; citation_publication_date=2015; citation_pages=35202-17; citation_id=CR23"/>
    <meta name="citation_reference" content="citation_journal_title=J Clin Oncol; citation_title=Precision Medicine in DLBCL: Are We There Yet?; citation_author=AJ Davies; citation_volume=39; citation_publication_date=2021; citation_pages=1314-6; citation_id=CR24"/>
    <meta name="citation_reference" content="citation_journal_title=Mol Cancer Ther; citation_title=Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background; citation_author=BR Davies, H Greenwood, P Dudley, C Crafter, DH Yu, J Zhang; citation_volume=11; citation_publication_date=2012; citation_pages=873-87; citation_id=CR25"/>
    <meta name="citation_reference" content="citation_journal_title=Nat Med; citation_title=ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets; citation_author=AJ Souers, JD Leverson, ER Boghaert, SL Ackler, ND Catron, J Chen; citation_volume=19; citation_publication_date=2013; citation_pages=202-8; citation_id=CR26"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin&#8217;s lymphoma; citation_author=DG Maloney, AJ Grillo-Lopez, CA White, D Bodkin, RJ Schilder, JA Neidhart; citation_volume=90; citation_publication_date=1997; citation_pages=2188-95; citation_id=CR27"/>
    <meta name="citation_reference" content="citation_journal_title=Int J Oncol; citation_title=Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models; citation_author=C Crafter, JP Vincent, E Tang, P Dudley, NH James, T Klinowska; citation_volume=47; citation_publication_date=2015; citation_pages=446-54; citation_id=CR28"/>
    <meta name="citation_reference" content="citation_journal_title=Leukemia; citation_title=mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma; citation_author=W Xu, P Berning, T Erdmann, M Grau, N Bettazova, M Zapukhlyak; citation_volume=37; citation_publication_date=2023; citation_pages=178-89; citation_id=CR29"/>
    <meta name="citation_reference" content="citation_journal_title=J Pharm Pharmacother; citation_title=Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research; citation_author=C Kilkenny, WJ Browne, IC Cuthill, M Emerson, DG Altman; citation_volume=1; citation_publication_date=2010; citation_pages=94-99; citation_id=CR30"/>
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor; citation_author=A Brunet, A Bonni, MJ Zigmond, MZ Lin, P Juo, LS Hu; citation_volume=96; citation_publication_date=1999; citation_pages=857-68; citation_id=CR31"/>
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B; citation_author=DAE Cross, DR Alessi, P Cohen, M Andjelkovich, BA Hemmings; citation_volume=378; citation_publication_date=1995; citation_pages=785-9; citation_id=CR32"/>
    <meta name="citation_reference" content="citation_journal_title=J Biol Chem; citation_title=Identification of a proline-rich Akt substrate as a 14-3-3 binding partner; citation_author=KS Kovacina, GY Park, SS Bae, AW Guzzetta, E Schaefer, MJ Birnbaum; citation_volume=278; citation_publication_date=2003; citation_pages=10189-94; citation_id=CR33"/>
    <meta name="citation_reference" content="citation_journal_title=J Biol Chem; citation_title=Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B; citation_author=G Rena, S Guo, SC Cichy, TG Unterman, P Cohen; citation_volume=274; citation_publication_date=1999; citation_pages=17179-83; citation_id=CR34"/>
    <meta name="citation_reference" content="citation_journal_title=EMBO J; citation_title=Mechanism of activation of protein kinase B by insulin and IGF-1; citation_author=DR Alessi, M Andjelkovic, B Caudwell, P Cron, N Morrice, P Cohen; citation_volume=15; citation_publication_date=1996; citation_pages=6541-51; citation_id=CR35"/>
    <meta name="citation_reference" content="citation_journal_title=Curr Biol; citation_title=Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B&#945;; citation_author=DR Alessi, SR James, CP Downes, AB Holmes, PRJ Gaffney, CB Reese; citation_volume=7; citation_publication_date=1997; citation_pages=261-9; citation_id=CR36"/>
    <meta name="citation_reference" content="citation_journal_title=J Biol Chem; citation_title=mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes; citation_author=RC Hresko, M Mueckler; citation_volume=280; citation_publication_date=2005; citation_pages=40406-16; citation_id=CR37"/>
    <meta name="citation_reference" content="citation_journal_title=Cell; citation_title=SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity; citation_author=E Jacinto, V Facchinetti, D Liu, N Soto, S Wei, SY Jung; citation_volume=127; citation_publication_date=2006; citation_pages=125-37; citation_id=CR38"/>
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex; citation_author=DD Sarbassov, DA Guertin, SM Ali, DM Sabatini; citation_volume=307; citation_publication_date=2005; citation_pages=1098-101; citation_id=CR39"/>
    <meta name="citation_reference" content="citation_journal_title=Mol Cell Biol; citation_title=Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B; citation_author=MP Scheid, PA Marignani, JR Woodgett; citation_volume=22; citation_publication_date=2002; citation_pages=6247-60; citation_id=CR40"/>
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Protein kinase B kinases that mediate phosphatidylinositol 3,4,5- trisphosphate-dependent activation of protein kinase B; citation_author=L Stephens, K Anderson, D Stokoe, H Erdjument-Bromage, GF Painter, AB Holmes; citation_volume=279; citation_publication_date=1998; citation_pages=710-4; citation_id=CR41"/>
    <meta name="citation_reference" content="citation_journal_title=Oncogene; citation_title=Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis; citation_author=M Herrant, A Jacquel, S Marchetti, N Belhacene, P Colosetti, F Luciano; citation_volume=23; citation_publication_date=2004; citation_pages=7863-73; citation_id=CR42"/>
    <meta name="citation_reference" content="citation_journal_title=J Biol Chem; citation_title=Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells; citation_author=C Weng, Y Li, D Xu, Y Shi, H Tang; citation_volume=280; citation_publication_date=2005; citation_pages=10491-10500; citation_id=CR43"/>
    <meta name="citation_reference" content="citation_journal_title=Cell Death Differ; citation_title=Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario; citation_author=JE Chipuk, L Bouchier-Hayes, DR Green; citation_volume=13; citation_publication_date=2006; citation_pages=1396-402; citation_id=CR44"/>
    <meta name="citation_reference" content="citation_journal_title=Trends Cell Biol; citation_title=How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?; citation_author=JE Chipuk, DR Green; citation_volume=18; citation_publication_date=2008; citation_pages=157-64; citation_id=CR45"/>
    <meta name="citation_reference" content="citation_journal_title=Cell Death Differ; citation_title=BCL-2 family proteins: changing partners in the dance towards death; citation_author=J Kale, EJ Osterlund, DW Andrews; citation_volume=25; citation_publication_date=2018; citation_pages=65-80; citation_id=CR46"/>
    <meta name="citation_reference" content="citation_journal_title=Nat Rev Mol Cell Biol; citation_title=Mitochondria and cell death: outer membrane permeabilization and beyond; citation_author=SW Tait, DR Green; citation_volume=11; citation_publication_date=2010; citation_pages=621-32; citation_id=CR47"/>
    <meta name="citation_reference" content="citation_journal_title=Biotechnol Bioeng; citation_title=BAK and BAX deletion using zinc-finger nucleases yields apoptosis-resistant CHO cells; citation_author=GJ Cost, Y Freyvert, A Vafiadis, Y Santiago, JC Miller, E Rebar; citation_volume=105; citation_publication_date=2010; citation_pages=330-40; citation_id=CR48"/>
    <meta name="citation_reference" content="citation_journal_title=Mol Cell; citation_title=The Combined Functions of Proapoptotic Bcl-2 Family Members Bak and Bax Are Essential for Normal Development of Multiple Tissues; citation_author=T Lindsten, AJ Ross, A King, W-X Zong, JC Rathmell, HA Shiels; citation_volume=6; citation_publication_date=2000; citation_pages=1389-99; citation_id=CR49"/>
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death; citation_author=MC Wei, WX Zong, EHY Cheng, T Lindsten, V Panoutsakopoulou, AJ Ross; citation_volume=292; citation_publication_date=2001; citation_pages=727-30; citation_id=CR50"/>
    <meta name="citation_reference" content="citation_journal_title=Lab Invest; citation_title=Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas; citation_author=R Jaksa, J Karolova, M Svaton, D Kazantsev, M Grajciarova, E Pokorna; citation_volume=102; citation_publication_date=2022; citation_pages=957-65; citation_id=CR51"/>
    <meta name="citation_reference" content="citation_journal_title=Clin Cancer Res; citation_title=Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma; citation_author=M Klanova, L Andera, J Brazina, J Svadlenka, S Benesova, J Soukup; citation_volume=22; citation_publication_date=2016; citation_pages=1138-49; citation_id=CR52"/>
    <meta name="citation_reference" content="citation_journal_title=NPJ Breast Cancer; citation_title=Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models; citation_author=L Hopcroft, EM Wigmore, SC Williamson, S Ros, C Eberlein, JI Moss; citation_volume=9; citation_publication_date=2023; citation_id=CR53"/>
    <meta name="citation_reference" content="citation_journal_title=Br J Cancer; citation_title=Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer; citation_author=C Eberlein, SC Williamson, L Hopcroft, S Ros, JI Moss, J Kerr; citation_volume=130; citation_publication_date=2024; citation_pages=1377-87; citation_id=CR54"/>
    <meta name="citation_reference" content="citation_journal_title=Oncotarget; citation_title=Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen; citation_author=JT Lynch, R McEwen, C Crafter, U McDermott, MJ Garnett, ST Barry; citation_volume=7; citation_publication_date=2016; citation_pages=22128-39; citation_id=CR55"/>
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL; citation_author=K Bojarczuk, K Wienand, JA Ryan, L Chen, M Villalobos-Ortiz, E Mandato; citation_volume=133; citation_publication_date=2019; citation_pages=70-80; citation_id=CR56"/>
    <meta name="citation_reference" content="citation_journal_title=Clin Cancer Res; citation_title=Inhibiting PI3Kbeta with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors; citation_author=JT Lynch, UM Polanska, O Delpuech, U Hancox, AG Trinidad, F Michopoulos; citation_volume=23; citation_publication_date=2017; citation_pages=7584-95; citation_id=CR57"/>
    <meta name="citation_reference" content="citation_journal_title=Mol Cancer Ther; citation_title=Combined Inhibition of PI3Kbeta and mTOR Inhibits Growth of PTEN-null Tumors; citation_author=JT Lynch, UM Polanska, U Hancox, O Delpuech, J Maynard, C Trigwell; citation_volume=17; citation_publication_date=2018; citation_pages=2309-19; citation_id=CR58"/>
    <meta name="citation_reference" content="citation_journal_title=Int J Biol Sci; citation_title=The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer; citation_author=F Fontana, G Giannitti, S Marchesi, P Limonta; citation_volume=20; citation_publication_date=2024; citation_pages=3113-25; citation_id=CR59"/>
    <meta name="citation_reference" content="citation_journal_title=Oncogene; citation_title=AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors; citation_author=S Dunn, C Eberlein, J Yu, A Gris-Oliver, SH Ong, U Yelland; citation_volume=41; citation_publication_date=2022; citation_pages=5046-60; citation_id=CR60"/>
    <meta name="citation_reference" content="citation_journal_title=Blood Cancer J; citation_title=Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment; citation_author=A Paulus, S Akhtar, H Yousaf, A Manna, SM Paulus, Y Bashir; citation_volume=7; citation_publication_date=2017; citation_id=CR61"/>
    <meta name="citation_reference" content="citation_journal_title=Clin Cancer Res; citation_title=Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas; citation_author=LV Pham, S Huang, H Zhang, J Zhang, T Bell, S Zhou; citation_volume=24; citation_publication_date=2018; citation_pages=3967-80; citation_id=CR62"/>
    <meta name="citation_reference" content="citation_journal_title=Oncotarget; citation_title=MCL-1-independent mechanisms of synergy between dual PI3K/ mTOR and BCL-2 inhibition in diffuse large B cell lymphoma; citation_author=J Scott Lee, SS Tang, V Ortiz, TT Vo, DA Fruman; citation_volume=6; citation_publication_date=2015; citation_pages=35202-17; citation_id=CR63"/>
    <meta name="citation_reference" content="citation_journal_title=Mol Cancer Res; citation_title=Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt&#8217;s lymphoma cells to BH3 mimetics; citation_author=LC Spender, GJ Inman; citation_volume=10; citation_publication_date=2012; citation_pages=347-59; citation_id=CR64"/>
    <meta name="citation_reference" content="citation_journal_title=Blood Cancer J; citation_title=Loss in MCL-1 function sensitizes non-Hodgkin&#8217;s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199); citation_author=DC Phillips, Y Xiao, LT Lam, E Litvinovich, L Roberts-Rapp, AJ Souers; citation_volume=5; citation_publication_date=2015; citation_id=CR65"/>
    <meta name="citation_reference" content="citation_journal_title=Nat Commun; citation_title=Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia; citation_author=AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin; citation_volume=9; citation_publication_date=2018; citation_id=CR66"/>
    <meta name="citation_reference" content="citation_journal_title=Cancer Res; citation_title=Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells; citation_author=M Rahmani, J Nkwocha, E Hawkins, X Pei, RE Parker, M Kmieciak; citation_volume=78; citation_publication_date=2018; citation_pages=3075-86; citation_id=CR67"/>
    <meta name="citation_reference" content="citation_journal_title=EMBO Rep; citation_title=Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance; citation_author=J Kale, O Kutuk, GC Brito, TS Andrews, B Leber, A Letai; citation_volume=19; citation_publication_date=2018; citation_pages=e45235; citation_id=CR68"/>
    <meta name="citation_reference" content="citation_journal_title=Cell death Dis; citation_title=Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-&#954;B directly regulates PUMA-dependent apoptosis; citation_author=L Sun, Y Huang, Y Liu, Y Zhao, X He, L Zhang; citation_volume=9; citation_publication_date=2018; citation_pages=911; citation_id=CR69"/>
    <meta name="citation_author" content="Willis, Brandon S."/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Mongeon, Kevin"/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Dry, Hannah"/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Neveras, India L."/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Bryan, Nadezda"/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Pandya, Meghana"/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Roderick-Richardson, Justine"/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Xu, Wendan"/>
    <meta name="citation_author_institution" content="Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital M&#252;nster, M&#252;nster, Germany"/>
    <meta name="citation_author" content="Yang, Li"/>
    <meta name="citation_author_institution" content="Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital M&#252;nster, M&#252;nster, Germany"/>
    <meta name="citation_author" content="Rosen, Alan"/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Reimer, Corinne"/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Tuskova, Liliana"/>
    <meta name="citation_author_institution" content="Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic"/>
    <meta name="citation_author" content="Klener, Pavel"/>
    <meta name="citation_author_institution" content="Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic"/>
    <meta name="citation_author" content="Mettetal, Jerome T."/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Boston, USA"/>
    <meta name="citation_author" content="Lenz, Georg"/>
    <meta name="citation_author_institution" content="Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital M&#252;nster, M&#252;nster, Germany"/>
    <meta name="citation_author" content="Barry, Simon T."/>
    <meta name="citation_author_institution" content="Bioscience, Early Oncology, AstraZeneca, Cambridge, UK"/>
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access"/>
    <meta name="twitter:site" content="@LeukemiaJnl"/>
    <meta name="twitter:card" content="summary_large_image"/>
    <meta name="twitter:image:alt" content="Content cover image"/>
    <meta name="twitter:title" content="Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma"/>
    <meta name="twitter:description" content="Leukemia - Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma"/>
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig1_HTML.png"/>
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41375-024-02401-9"/>
    <meta property="og:type" content="article"/>
    <meta property="og:site_name" content="Nature"/>
    <meta property="og:title" content="Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma - Leukemia"/>
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig1_HTML.png"/>
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
</head>
<body class="article-page">

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1"
         class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide"
         data-ad-type="top"
         data-test="top-ad"
         data-pa11y-ignore
         data-gpt
         data-gpt-unitpath="/285/leu.nature.com/article"
         data-gpt-sizes="728x90"
         data-gpt-targeting="type=article;pos=top;artid=s41375-024-02401-9;doi=10.1038/s41375-024-02401-9;techmeta=13,60,64,95;subjmeta=1541,1990,2778,308,692,699;kwrd=Haematological+cancer,Preclinical+research">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/leu.nature.com/article&amp;sz=728x90&amp;c=-1490550348&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41375-024-02401-9%26doi%3D10.1038/s41375-024-02401-9%26techmeta%3D13,60,64,95%26subjmeta%3D1541,1990,2778,308,692,699%26kwrd%3DHaematological+cancer,Preclinical+research">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/leu.nature.com/article&amp;sz=728x90&amp;c=-1490550348&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41375-024-02401-9%26doi%3D10.1038/s41375-024-02401-9%26techmeta%3D13,60,64,95%26subjmeta%3D1541,1990,2778,308,692,699%26kwrd%3DHaematological+cancer,Preclinical+research"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header data-track-component="nature-150-split-header" style="border-color:#d01910">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/leu"
                           data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/leu/header-8e0456ae95ea87bcb43908932446b9bc.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/leu/header-8e0456ae95ea87bcb43908932446b9bc.svg" height="32" alt="Leukemia">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link"
                               data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search"
                                href="#search-menu"
                                data-header-expander
                                data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"/></svg><span>Search</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href='https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41375-024-02401-9'><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="#explore"
                                       class="c-header__link"
                                       data-header-expander
                                       data-test="menu-button--explore"
                                       data-track="click" data-track-action="open explore expander" data-track-label="button">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="#about-the-journal"
                                       class="c-header__link"
                                       data-header-expander
                                       data-test="menu-button--about-the-journal"
                                       data-track="click" data-track-action="open about the journal expander" data-track-label="button">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                    </a>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="#publish-with-us"
                                           class="c-header__link c-header__link--dropdown-menu"
                                           data-header-expander
                                           data-test="menu-button--publish"
                                           data-track="click" data-track-action="open publish with us expander" data-track-label="button">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"/></svg>
                                        </a>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link"
                                       href="https://journal-alerts.springernature.com/subscribe?journal_id&#x3D;41375"
                                       rel="nofollow"
                                       data-track="nav_sign_up_for_alerts"
                                       data-track-action="Sign up for alerts"
                                       data-track-label="link (desktop site header)"
                                       data-track-external>
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"/></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link"
                                       href="https://www.nature.com/leu.rss"
                                       data-track="click"
                                       data-track-action="rss feed"
                                       data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/leu" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:leukemia"><span itemprop="name">leukemia</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link"
                               href="/leu/articles?type&#x3D;article" itemprop="item"
                               data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10"
                                         xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z"
                                              fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container"  data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide"
                     id="js-enable-context-bar"
                     data-test="context-bar"
                     data-context-bar
                     aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41375-024-02401-9.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41375-024-02401-9.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2024-09-16">16 September 2024</time></li>
                    </ul>

                    <p class="c-article-title__super">LYMPHOMA</p><h1 class="c-article-title" data-test="article-title" data-article-title="">Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma</h1>
                    <ul class="c-article-author-list c-article-author-list--short" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="1_16" data-track-context="researcher popup with no profile" href="#auth-Brandon_S_-Willis-Aff1" data-author-popup="auth-Brandon_S_-Willis-Aff1" data-author-search="Willis, Brandon S.">Brandon S. Willis</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup><sup class="u-js-hide"> <a href="#na1">na1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="2_16" data-track-context="researcher popup with no profile" href="#auth-Kevin-Mongeon-Aff1" data-author-popup="auth-Kevin-Mongeon-Aff1" data-author-search="Mongeon, Kevin">Kevin Mongeon</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup><sup class="u-js-hide"> <a href="#na1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="3_16" data-track-context="researcher popup with no profile" href="#auth-Hannah-Dry-Aff1" data-author-popup="auth-Hannah-Dry-Aff1" data-author-search="Dry, Hannah">Hannah Dry</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="4_16" data-track-context="researcher popup with no profile" href="#auth-India_L_-Neveras-Aff1" data-author-popup="auth-India_L_-Neveras-Aff1" data-author-search="Neveras, India L.">India L. Neveras</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="5_16" data-track-context="researcher popup with no profile" href="#auth-Nadezda-Bryan-Aff1" data-author-popup="auth-Nadezda-Bryan-Aff1" data-author-search="Bryan, Nadezda">Nadezda Bryan</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="6_16" data-track-context="researcher popup with no profile" href="#auth-Meghana-Pandya-Aff1" data-author-popup="auth-Meghana-Pandya-Aff1" data-author-search="Pandya, Meghana">Meghana Pandya</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="7_16" data-track-context="researcher popup with no profile" href="#auth-Justine-Roderick_Richardson-Aff1" data-author-popup="auth-Justine-Roderick_Richardson-Aff1" data-author-search="Roderick-Richardson, Justine">Justine Roderick-Richardson</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="8_16" data-track-context="researcher popup with no profile" href="#auth-Wendan-Xu-Aff2" data-author-popup="auth-Wendan-Xu-Aff2" data-author-search="Xu, Wendan">Wendan Xu</a><sup class="u-js-hide"><a href="#Aff2">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="9_16" data-track-context="researcher popup with no profile" href="#auth-Li-Yang-Aff2" data-author-popup="auth-Li-Yang-Aff2" data-author-search="Yang, Li">Li Yang</a><sup class="u-js-hide"><a href="#Aff2">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="10_16" data-track-context="researcher popup with no profile" href="#auth-Alan-Rosen-Aff1" data-author-popup="auth-Alan-Rosen-Aff1" data-author-search="Rosen, Alan">Alan Rosen</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="11_16" data-track-context="researcher popup with no profile" href="#auth-Corinne-Reimer-Aff1" data-author-popup="auth-Corinne-Reimer-Aff1" data-author-search="Reimer, Corinne">Corinne Reimer</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="12_16" data-track-context="researcher popup with no profile" href="#auth-Liliana-Tuskova-Aff3" data-author-popup="auth-Liliana-Tuskova-Aff3" data-author-search="Tuskova, Liliana">Liliana Tuskova</a><sup class="u-js-hide"><a href="#Aff3">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="13_16" data-track-context="researcher popup with no profile" href="#auth-Pavel-Klener-Aff3" data-author-popup="auth-Pavel-Klener-Aff3" data-author-search="Klener, Pavel">Pavel Klener</a><sup class="u-js-hide"><a href="#Aff3">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="14_16" data-track-context="researcher popup with no profile" href="#auth-Jerome_T_-Mettetal-Aff1" data-author-popup="auth-Jerome_T_-Mettetal-Aff1" data-author-search="Mettetal, Jerome T.">Jerome T. Mettetal</a><sup class="u-js-hide"><a href="#Aff1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="15_16" data-track-context="researcher popup with no profile" href="#auth-Georg-Lenz-Aff2" data-author-popup="auth-Georg-Lenz-Aff2" data-author-search="Lenz, Georg">Georg Lenz</a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-4728-1693"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-4728-1693</a></span><sup class="u-js-hide"><a href="#Aff2">2</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 16 authors for this article" title="Show all 16 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" data-track-index="16_16" data-track-context="researcher popup with no profile" href="#auth-Simon_T_-Barry-Aff4" data-author-popup="auth-Simon_T_-Barry-Aff4" data-author-search="Barry, Simon T." data-corresp-id="c1">Simon T. Barry<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide"> 
            <a class="js-orcid" href="https://orcid.org/0000-0002-8511-0588"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-8511-0588</a></span><sup class="u-js-hide"><a href="#Aff4">4</a></sup> </li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/leu" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Leukemia</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span> 38</b>, <span class="u-visually-hidden">pages </span>2663–2674 (<span data-test="article-publication-year">2024</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">4686 <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">7 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41375-024-02401-9/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
                
            </ul>
        </div>
    
                    
                </header>

                
    <div class="u-js-hide" data-component="article-subject-links">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/haematological-cancer" data-track="click" data-track-action="view subject" data-track-label="link">Haematological cancer</a></li><li class="c-article-subject-list__subject"><a href="/subjects/pre-clinical-studies" data-track="click" data-track-action="view subject" data-track-label="link">Preclinical research</a></li>
        </ul>
    </div>

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>The therapeutic potential of targeting PI3K/AKT/PTEN signalling in B-cell malignancies remains attractive. Whilst PI3K-α/δ inhibitors demonstrate clinical benefit in certain B-cell lymphomas, PI3K signalling inhibitors have been inadequate in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in part, due to treatment related toxicities. Clinically, AKT inhibitors exhibit a differentiated tolerability profile offering an alternative approach for treating patients with B-cell malignancies. To explore how AKT inhibition complements other potential therapeutics in the treatment of DLBCL patients, an in vitro combination screen was conducted across a panel of DLCBL cell lines. The AKT inhibitor, capivasertib, in combination with the BCL-2 inhibitor, venetoclax, produced notable therapeutic benefit in preclinical models of DLBCL. Capivasertib and venetoclax rapidly induced caspase and PARP cleavage in GCB-DLBCL <i>PTEN</i> wildtype cell lines and those harbouring <i>PTEN</i> mutations or reduced PTEN protein, driving prolonged tumour growth inhibition in DLBCL cell line and patient derived xenograft lymphoma models. The addition of the rituximab further deepened the durability of capivasertib and venetoclax responses in a RCHOP refractory DLBCL in vivo models. These findings provide preclinical evidence for the rational treatment combination of AKT and BCL-2 inhibitors using capivasertib and venetoclax respectively alongside anti-CD20 antibody supplementation for treatment of patients with DLBCL.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41375-021-01470-4/MediaObjects/41375_2021_1470_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s41375-021-01470-4?fromPaywallRec=false"
                                           data-track="select_recommendations_1"
                                           data-track-context="inline recommendations"
                                           data-track-action="click recommendations inline - 1"
                                           data-track-label="10.1038/s41375-021-01470-4">Inhibitors of Bcl-2 and Bruton’s tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">18 November 2021</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41375-022-01749-0/MediaObjects/41375_2022_1749_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s41375-022-01749-0?fromPaywallRec=false"
                                           data-track="select_recommendations_2"
                                           data-track-context="inline recommendations"
                                           data-track-action="click recommendations inline - 2"
                                           data-track-label="10.1038/s41375-022-01749-0">mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">09 November 2022</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41408-025-01214-y/MediaObjects/41408_2025_1214_Figa_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link"
                                           itemprop="url"
                                           href="https://www.nature.com/articles/s41408-025-01214-y?fromPaywallRec=false"
                                           data-track="select_recommendations_3"
                                           data-track-context="inline recommendations"
                                           data-track-action="click recommendations inline - 3"
                                           data-track-label="10.1038/s41408-025-01214-y">Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">02 February 2025</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1750447690,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Introduction"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Introduction</h2><div class="c-article-section__content" id="Sec1-content"><p>Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype with approximately 30–40% of cases worldwide [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90." href="/articles/s41375-024-02401-9#ref-CR1" id="ref-link-section-d98262920e635">1</a>]. DLBCL is a heterogenous B cell malignancy defined by both genetic and epigenetic alterations that regulate cell growth, survival and differentiation [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37:551–68.e14." href="/articles/s41375-024-02401-9#ref-CR2" id="ref-link-section-d98262920e638">2</a>]. Generally, DLBCL is transcriptionally subclassified into two major subset types, activated B-cell like (ABC) and germinal centre B-cell like (GCB) derived from distinct originating B cell populations. Genomic analyses have identified distinct subtypes of DLBCL with genetic drivers and signalling pathways that are therapeutically targetable [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Roschewski M, Phelan JD, Wilson WH. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. Cancer J. 2020;26:195–205." href="/articles/s41375-024-02401-9#ref-CR3" id="ref-link-section-d98262920e641">3</a>]. First line therapy for DLBCL largely consists of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP), or more recently, a modified regimen substituting vincristine for polatuzumab vedotin (pola-R-CHP) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl J Med. 2022;386:351–63." href="/articles/s41375-024-02401-9#ref-CR4" id="ref-link-section-d98262920e644">4</a>]. Despite these recent improvements in first line therapies, relapsed/refractory DLBCL patients still require novel treatment regimens.</p><p>Activation of the canonical phosphoinositide-(3)-kinase (PI3K), AKT and mammalian target of rapamycin (mTOR) signalling pathway is frequently dysregulated across B-cell malignancies [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, et al. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017;187:1700–16." href="/articles/s41375-024-02401-9#ref-CR5" id="ref-link-section-d98262920e650">5</a>]. There are frequent mutations found in <i>PIK3CA</i> and <i>PTEN</i>, including down-regulation of PTEN expression in GCB DLBCL [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Pfeifer M, Lenz G. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma. Cell Cycle. 2013;12:3347–8." href="/articles/s41375-024-02401-9#ref-CR6" id="ref-link-section-d98262920e659">6</a>]. PI3K-AKT pathway inhibitors show differential activity in ABC- versus GCB-DLBCL subclassifications. ABC-DLBCL, which harbour PIK3CA mutations, is sensitive to PI3Kα and PI3Kδ inhibitors [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22." href="#ref-CR7" id="ref-link-section-d98262920e662">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Pongas GN, Annunziata CM, Staudt LM. PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma. Oncotarget. 2017;8:81794–802." href="#ref-CR8" id="ref-link-section-d98262920e662_1">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23:826–38." href="/articles/s41375-024-02401-9#ref-CR9" id="ref-link-section-d98262920e666">9</a>]. Copanlisib, a pan-PI3K inhibitor with PI3Kα and δ activity has clinical activity in follicular lymphoma and has been evaluated in ABC-DLBCL [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–78." href="/articles/s41375-024-02401-9#ref-CR10" id="ref-link-section-d98262920e669">10</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34:2184–97." href="/articles/s41375-024-02401-9#ref-CR11" id="ref-link-section-d98262920e672">11</a>]. Safety concerns associated with long-term treatment limits the utility of PI3K inhibitors such as copanlisib and idelalisib. Modulation of the PI3K signalling axis at distinct pathway nodes such as AKT is feasible using the small molecule pan-AKT inhibitor, capivasertib, which has an acceptable safety profile and shown positive benefit in a Phase III clinical trial and FDA approval in combination with fulvestrant for the treatment of hormone receptor positive breast cancer [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N. Engl J Med. 2023;388:2058–70." href="/articles/s41375-024-02401-9#ref-CR12" id="ref-link-section-d98262920e675">12</a>].</p><p>Relapsed/refractory GCB-DLBCL has a high incidence of PTEN protein loss [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Pfeifer M, Lenz G. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma. Cell Cycle. 2013;12:3347–8." href="/articles/s41375-024-02401-9#ref-CR6" id="ref-link-section-d98262920e681">6</a>], and GCB DLBCL cell lines and tumour models are sensitivity to AKT inhibition [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22." href="/articles/s41375-024-02401-9#ref-CR7" id="ref-link-section-d98262920e684">7</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, et al. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. 2016;7:9163–74." href="/articles/s41375-024-02401-9#ref-CR13" id="ref-link-section-d98262920e687">13</a>], underscoring the importance of the PI3K-AKT signalling axis in GCB-DLBCL. This is further supported by the observation that combined PI3Kβ/δ and mTORC1/2 inhibition has broad efficacy across preclinical DLBCL models [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021;138:1110–9." href="/articles/s41375-024-02401-9#ref-CR14" id="ref-link-section-d98262920e690">14</a>]. PI3K-AKT signalling pathways in DLBCL are therefore essential in different subtypes whilst the key pathway node for therapeutic modulation varies amongst subtypes.</p><p>R-CHOP is the conventional treatment for patients with DLBCL, along with the recent approval of Pola-R-CHP [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 4" title="Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl J Med. 2022;386:351–63." href="/articles/s41375-024-02401-9#ref-CR4" id="ref-link-section-d98262920e696">4</a>]. Additionally, clinical benefit in patients with various haematological malignancies has been observed using the B-cell lymphoma-2 (BCL-2) inhibitor venetoclax which induces apoptosis [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Cory S, Roberts AW, Colman PM, Adams JM. Targeting BCL-2-like Proteins to Kill Cancer Cells. Trends Cancer. 2016;2:443–60." href="/articles/s41375-024-02401-9#ref-CR15" id="ref-link-section-d98262920e699">15</a>]. Venetoclax is approved for newly diagnosed and relapse/refractory adult patients with chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma with 17p deletion, and for newly diagnosed acute myeloid leukaemia patients in combination with various hypomethylating agents [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N. Engl J Med. 2020;383:617–29." href="/articles/s41375-024-02401-9#ref-CR16" id="ref-link-section-d98262920e702">16</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–78." href="/articles/s41375-024-02401-9#ref-CR17" id="ref-link-section-d98262920e705">17</a>]. In Phase II clinical trial, addition of venetoclax to RCHOP enhanced clinical benefit in high risk DLBCL patients [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600–9." href="/articles/s41375-024-02401-9#ref-CR19" id="ref-link-section-d98262920e708">19</a>]. Preclinically, venetoclax combined with an epigenetic EZH2 inhibitor extended survival benefit of DLBCL PDX mouse models [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4:5226–31." href="/articles/s41375-024-02401-9#ref-CR18" id="ref-link-section-d98262920e712">18</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 19" title="Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600–9." href="/articles/s41375-024-02401-9#ref-CR19" id="ref-link-section-d98262920e715">19</a>]. Finally, venetoclax resistance in DLBCL cell lines associates with AKT signalling activation, suggesting that AKT antagonism could improve venetoclax response [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593." href="#ref-CR20" id="ref-link-section-d98262920e718">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008;7:3265–74." href="#ref-CR21" id="ref-link-section-d98262920e718_1">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011;71:5204–13." href="#ref-CR22" id="ref-link-section-d98262920e718_2">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202–17." href="/articles/s41375-024-02401-9#ref-CR23" id="ref-link-section-d98262920e721">23</a>].</p><p>Given PI3K-AKT dependency in DLBCL, combination of capivasertib and venetoclax along with an anti-CD20 antibody, rituximab could present a unique therapeutic opportunity for patients with relapse/refractory DLBCL [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Davies AJ. Precision Medicine in DLBCL: Are We There Yet? J Clin Oncol. 2021;39:1314–6." href="#ref-CR24" id="ref-link-section-d98262920e728">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873–87." href="#ref-CR25" id="ref-link-section-d98262920e728_1">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8." href="#ref-CR26" id="ref-link-section-d98262920e728_2">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–95." href="/articles/s41375-024-02401-9#ref-CR27" id="ref-link-section-d98262920e731">27</a>]. Herein, we provide preclinical evidence of capivasertib and venetoclax combinations along with the addition of rituximab as an attractive, novel treatment regimen for treatment of GCB DLBCL. Specifically, this combination rapidly activates caspases leading to robust tumour cell death driving anti-tumour efficacy in preclinical models of relapse/refractory DLBCL.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Methods</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Combination screen</h3><p>The combination of capivasertib and venetoclax was evaluated in an in vitro DLBCL cell panel proliferation screen as previously published [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, et al. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. Int J Oncol. 2015;47:446–54." href="/articles/s41375-024-02401-9#ref-CR28" id="ref-link-section-d98262920e746">28</a>]. Cells were seeded between 1000–8000 cells per well in 384-well plate. 24 h after plating cells were treated for 120 h with a 6-point dose response (0.03–3 µM) in a combination matrix (6 × 6) using an Echo 555 acoustic dispenser (Labcyte). Live cells were quantified using an imaging-based assay utilising Sytox Green (ThermoFisher, MA) and saponin (Sigma–Aldrich, MO) to permeabilise the cells. Cell proliferation versus cell death was determine by comparing Day 0 (pre-treatment) and 72 or 120 h (post-treatment). Percentage growth was calculated from the live cell number. Two-dimensional dose response matrix and curve fitting were processed in the combination extension of Genedata Screener 13™ (Genedata AG, Basel,Switzerland) as previously described [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, et al. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. Int J Oncol. 2015;47:446–54." href="/articles/s41375-024-02401-9#ref-CR28" id="ref-link-section-d98262920e749">28</a>]. Combination activity was calculated using the Loewe dose-additivity model using a synergy score cut-off &gt;5.</p><h3 class="c-article__sub-heading" id="Sec4">Cell line culture and reagents</h3><p>DNA fingerprinting short tandem repeat authentication of cell lines was performed. Culture media are listed in supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM1">S1</a>. In caspase-glo 3/7 (Promega, WI) experiments, cells were pre-treated overnight with Q-VD-OPH (50 µM) (Cayman Chemical, MI) or vehicle prior to seeding. Capivasertib (AZD5363) was synthesized at AstraZeneca. Venetoclax was purchased from Medkoo Biosciences (Durham, NC). Generation of stable genetic knockout cell lines using Ribonucleoprotein (RNP) nucleofection was conducted using the NEON electroporation system (Invitrogen, CA). Details on the sgRNAs are captured in supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM1">S3</a>.</p><h3 class="c-article__sub-heading" id="Sec5">Biomarker analysis</h3><p>Western blots were performed as previously described [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178–89." href="/articles/s41375-024-02401-9#ref-CR29" id="ref-link-section-d98262920e774">29</a>]. Cells were lysed in Phosphosafe lysis reagent (EMD Millipore, MA) supplemented with 1X HALT Protease and Phosphatase Inhibitor (PPI) Cocktail (Thermo Fisher, MA). A 1% (w/v) SDS, 10% (v/v) glycerol, 0.1 M Tris-HCl (pH 6.8) lysis buffer supplemented with 1:1000 benzonase (Sigma Aldrich, MO) and HALT PPI cocktail was used for protein extraction to probe for BAK and BAX. Horseradish peroxidase–linked secondary antibodies (Cell Signalling Technology, MA) and DETECTED Pierce ECL SuperSignal™ West Pico PLUS Chemiluminescent Substrate or Femto Maximum Sensitivity Substrate (Thermo Fisher, MA) were used to detect immune complexes. Cytochrome c release assay kit was performed according to manufacturer instructions (Abcam, UK). Primary antibodies details are shown in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM1">S2</a>.</p><h3 class="c-article__sub-heading" id="Sec6">In vivo studies ethics approvals</h3><p>All cell line models were conducted in accordance with the AstraZeneca IACUC (Institutional Animal Care and Use Committee) and reported following the ARRIVE (Animal Research: Reporting In Vivo experiments) guidelines [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharm Pharmacother. 2010;1:94–99." href="/articles/s41375-024-02401-9#ref-CR30" id="ref-link-section-d98262920e788">30</a>]. PDX studies involving the use of laboratory animals conducted in the Center for Experimental Biomodels of the First Faculty of Medicine, Charles University in Prague, Czech Republic, were reviewed and approved by the Institutional Animal Welfare Committee and by the Ministry of Agriculture of the Czech Republic, as well as by the Research and Higher Education section of the Ministry of Education, Youth and Sports of the Czech Republic under the number 592/15 (MSMT-11255/2015-4).</p><h3 class="c-article__sub-heading" id="Sec7">In vivo studies</h3><p>Cell line derived models were powered according to the AstraZeneca powering tool depending on degree of anti-tumour response anticipated. For PDX models a minimal of 8 animals per group was used. Studies were performed independent of the lead investigators, though compound identity was not blinded. No animals were excluded. Animals were randomized to a consistent mean tumour size per group. All calculations were performed using AstraZeneca. Tumour volume was calculated according to the following formula: π/6 × length × width × height). Statistical analyses. Data shown in graphs are mean ± SEM. Statistical analyses (t-test, multiple comparisons) were performed using GraphPad Prism (version8.4.3). Mouse xenograft models of DLCBL cell lines. Ten million SuDHL4 and WSU-DLCL2 or five million SUDHL5 cells in PBS mixed with 50:50 with Matrigel™ (Beckton Dickinson, Franklin Lakes, NJ, USA) were implanted subcutaneously into the right flank of CB-17 <i>scid</i> female mice. For efficacy studies, growth inhibition from the start of treatment was assessed by comparison of the differences in tumour volume between control and treated groups. Statistical significance was evaluated using a one-tailed, 2-sample <i>t</i> test. Capivasertib was formulated as an oral solution in 10% DMSO/25% Kleptose and dosed 130 mg/kg BID. Venetoclax was formulated as an oral suspension in 60% Phosal 50 PG, 30% polyethylene glycol 400, 10% ethanol. A 4 h gap was provided between each agent with capivasertib dosed first. Long term administration of venetoclax in combination with capivasertib was associated with body weight loss. Dosing holidays were provided and food supplementation when body weight loss was greater than 10–12% for an individual mouse. Body weight loss is because of glucose dysregulation is a common mouse toxicity following inhibition of PI3K-AKT signalling. RCHOP was administered once; Rituxan® (rituximab) 10 mg/kg intraperitoneal, Cytoxan® (cyclophosphamide) 25 mg/kg intraperitoneal, Doxil® (doxorubicin hydrochloride) 3 mg/kg intravenous, Oncovin® (vincristine sulfate) 0.25 mg/kg intravenous, Deltasone® (prednisolone) 0.5 mg/kg by oral gavage, each according to manufacturer’s instructions. Patient Derived Xenograft mouse model of DLBCL. For EBV-negative PDX models, six- to eight-week-old female NOD.Cg-Prkdc severe combined immunodeficiency Il2rgtm1Wjl/SzJ (NSG; Jackson Laboratory, ME, USA) mice were used.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec8-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec8">Results</h2><div class="c-article-section__content" id="Sec8-content"><h3 class="c-article__sub-heading" id="Sec9">Combined AKT and BCL-2 inhibition is effective in wildtype and PTEN-deficient DLBCL cell lines</h3><p>Capivasertib monotherapy treatment is effective in GCB DLBCL cell lines and xenograft models [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22." href="/articles/s41375-024-02401-9#ref-CR7" id="ref-link-section-d98262920e819">7</a>]. In an attempt to deliver a deeper anti-tumoral response, the activity of capivasertib and venetoclax was explored across a panel of 26 DLBCL cell lines. The panel of 7 ABC, 14 GCB, and 5 unclassified DLBCL cell lines had heterogenous levels of AKT pathway activation, PTEN protein and anti-apoptotic cell death proteins BCL-2, BCL-2-like 1 (BCL-XL) and MCL-1 expression (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig1">1A</a>). Due to limits in screening capacity, representative lines that capture the DLBCL landscape were selected for a 3-day combination proliferation screen. Monotherapy anti-proliferative responses (GI<sub>50</sub>) with capivasertib were enriched in PTEN deficient cell lines whereas venetoclax monotherapy resulted in cell death (AC<sub>50</sub>) in GCB-DLCBL and ABC-DLCBCL subtypes (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig1">1B</a>). Capivasertib and venetoclax exhibited strong combination activity (determined by Loewe score), predominantly in the GCB-DLCBL subcategory regardless of PTEN status (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig1">1C</a>), although certain pAKT and BCL-2 positive lines were insensitive to the combination.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Capivasertib and venetoclax combination results in rapid caspase-mediated cell death in responsive DLBCL models."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Capivasertib and venetoclax combination results in rapid caspase-mediated cell death in responsive DLBCL models.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="973"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>A</b> Base line Western blot biomarker profiling of ABC-, GCB-, and unclassified-DLBCL cell models with the OCI-LY1 cell line serving as reference control. <b>B</b> Capivasertib monotherapy anti-proliferative activity (GI<sub>50</sub>) (μM) and venetoclax monotherapy apoptotic response (Log AC<sub>50</sub>) (M) across GCB- and ABC-DLBCL cell lines. Order of cell lines is identical to that shown at the bottom of (<b>C</b>). <b>C</b> Loewe synergy scores for the combination of capivasertib and venetoclax in GCB- and ABC-DLBCL cell lines. + and – indicates each cell line’s monotherapy sensitivity to either capivasertib or venetoclax. Order of cell lines identical to that shown in (<b>B</b>). <b>D</b> Time course of caspase-3/7 activity in a cell model unresponsive to the either monotherapy or combination (TMD8), and two responsive models: WSU-DLCL2 (PTEN-mutant; GCB) and SUDHL-4 (PTEN wild-type; GCB) (<i>n</i> = 3/group). <b>E</b> Relative cell proliferation of SUDHL4, WSU-DLCL2 and TMD8 cell lines pretreated overnight with the pan-caspase inhibitor Q-VD-OPH (50 µM) or vehicle and then dosed with compounds for 24 h (<i>n</i> = 5/group; 2-way ANOVA with Sidak’s multiple comparisons ****<i>p</i> &lt; 0.0001). Staurosporine (5 µM) was a positive control for caspase induction and cell killing.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>To investigate changes following combination treatment, sensitive PTEN-wild-type (SUDHL-4) and PTEN-deficient (WSU-DLCL2) GCB-DLBCL, as well as an insensitive PTEN wild-type (TMD8, OCI-LY10, U2932), ABC-DLBCL cell lines were evaluated (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig1">1D</a>, Supp. Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">1A</a>). Combination treatment induced rapid induction of caspase 3/7 within 4 h, which was maintained at 24 h in SUDHL-4 and WSU-DLCL2 cell lines whereas the insensitive PTEN wild type cells lacked caspase induction (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig1">1D</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">1A</a>). Interestingly in the PTEN-deficient U2932 cell line whilst combination treatment did not increase caspase 3/7 induction, over long-term treatment a combination benefit was observed, with reduced proliferation versus both monotherapy treatments suggesting acute induction of apoptosis is not necessary for combination benefit (Supp. Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">1B</a>). Pharmacological rescue of sensitive GCB-DLBCL cell lines with Q-VD-OPH, a pan-caspase inhibitor, confirmed caspase-mediated cell death (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig1">1E</a>). In general, the combination induced extensive cell death within 24 h, suggesting that targeting AKT and BCL-2 has potential to enhance DLBCL tumour cell death.</p><h3 class="c-article__sub-heading" id="Sec10">Capivasertib and venetoclax combine to induce caspase-dependent cell death through BAK and BAX</h3><p>Next, biomarker changes associated with enhanced cell death in the SUDHL-4 and WSU-DLCL2 cells were evaluated. Consistent with the capivasertib mode of action, AKT phosphorylation is enhanced followed by a reduction in phosphorylation of AKT substrates (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2A</a>) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857–68." href="#ref-CR31" id="ref-link-section-d98262920e923">31</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–9." href="#ref-CR32" id="ref-link-section-d98262920e923_1">32</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278:10189–94." href="#ref-CR33" id="ref-link-section-d98262920e923_2">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999;274:17179–83." href="#ref-CR34" id="ref-link-section-d98262920e923_3">34</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541–51." href="#ref-CR35" id="ref-link-section-d98262920e923_4">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol. 1997;7:261–9." href="#ref-CR36" id="ref-link-section-d98262920e923_5">36</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280:40406–16." href="#ref-CR37" id="ref-link-section-d98262920e923_6">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–37." href="#ref-CR38" id="ref-link-section-d98262920e923_7">38</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101." href="#ref-CR39" id="ref-link-section-d98262920e923_8">39</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Scheid MP, Marignani PA, Woodgett JR. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol. 2002;22:6247–60." href="#ref-CR40" id="ref-link-section-d98262920e923_9">40</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5- trisphosphate-dependent activation of protein kinase B. Science. 1998;279:710–4." href="/articles/s41375-024-02401-9#ref-CR41" id="ref-link-section-d98262920e926">41</a>]. Despite elevated basal AKT activation in PTEN-deficient WSU-DLCL2 cells, capivasertib reduced phosphorylation of S6 kinase in both WSU-DLCL2 and SUDHL-4 cells (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2A</a>) indicating suppression of PI3K-AKT axis. Modulation of other substrates GSK3β and PRAS40 differed between cell lines indicating downstream signalling heterogeneity. Alterations in phosphorylation of FOXO and 4EBP1 were consistent with inhibition of AKT signalling (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2A</a>). Venetoclax monotherapy induced minimal PARP1 and caspase-3 cleavage in both WSU-DLCL2 and SUDHL-4 cell lines (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2A, B</a>). Following combination treatment modulation of AKT signalling emulated capivasertib monotherapy (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2A</a>). Capivasertib monotherapy had minimal effect on BCL-2 and BCL-XL protein levels or apoptotic biomarkers however, the combination increased PARP1 and caspase-3 cleavage in both GCB-DLBCL cell lines. At certain time points there were reductions in MCL-1 protein levels and MCL-1 cleavage in the SUDHL4 and WSU-DLCL2 cell line however these changes were variable and hence further work is required to determine whether these MCL changes make a contribution to efficacy (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2B, C</a>) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene. 2004;23:7863–73." href="/articles/s41375-024-02401-9#ref-CR42" id="ref-link-section-d98262920e945">42</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 2005;280:10491–10500." href="/articles/s41375-024-02401-9#ref-CR43" id="ref-link-section-d98262920e948">43</a>]. In the SUDHL4 and WSU-DLCL2 cell lines, combination treatment led to an enhancement in cytochrome c release into the cytoplasm relative to either monotherapy treatments (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">2A</a>). As expected, pre-treatment with Q-VD-OPH inhibited combination apoptosis induction (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2C</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Combination-mediated induction of cell death markers ablated by BAK/BAX codeletion in responsive DLBCL cell models."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Combination-mediated induction of cell death markers ablated by BAK/BAX codeletion in responsive DLBCL cell models.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/2" rel="nofollow"><picture><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="857"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p><b>A</b> Western blot profiling of the AKT signalling pathway, known AKT substrates, and (<b>B</b>) apoptotic markers in WSU-DLCL2 and SUDHL-4 when treated with capivasertib and venetoclax monotherapies and in combination at 2and 4 h. <b>C</b> Western blot profiling of apoptotic biomarkers time course of WSU-DLCL2 and SUDHL4 cell lines pretreated with vehicle (DMSO) or Q-VD-OPH (50 µM) then dosed with indicated compounds at 1, 2, and 4 h. <b>D</b> CRISPR/Cas9-mediated of single and double knockout (DKO) of BAK and BAX in WSU-DLCL2 and SUDHL4 cell lines. <b>E</b> Comparison of the induction of cell death markers between BAK/BAX wild-type and DKO WSU-DLCL2 and SUDHL4 cell lines when treated with compounds for 4 h.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Canonical apoptosis induction occurs through mitochondrial outer membrane pore (MOMP) formation with caspase activation preceding PARP1 cleavage and MCL-1 degradation (reviewed in [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 2006;13:1396–402." href="#ref-CR44" id="ref-link-section-d98262920e995">44</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18:157–64." href="#ref-CR45" id="ref-link-section-d98262920e995_1">45</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80." href="#ref-CR46" id="ref-link-section-d98262920e995_2">46</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621–32." href="/articles/s41375-024-02401-9#ref-CR47" id="ref-link-section-d98262920e998">47</a>]). To confirm canonical apoptotic pathway mechanisms, CRISPR/Cas9 gene editing was used to generate BAK and BAX deficient WSU-DLCL2 and SUDHL-4 cell lines with individual and tandem knock out of each gene s (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2D</a>) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Cost GJ, Freyvert Y, Vafiadis A, Santiago Y, Miller JC, Rebar E, et al. BAK and BAX deletion using zinc-finger nucleases yields apoptosis-resistant CHO cells. Biotechnol Bioeng. 2010;105:330–40." href="#ref-CR48" id="ref-link-section-d98262920e1004">48</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Lindsten T, Ross AJ, King A, Zong W-X, Rathmell JC, Shiels HA, et al. The Combined Functions of Proapoptotic Bcl-2 Family Members Bak and Bax Are Essential for Normal Development of Multiple Tissues. Mol Cell. 2000;6:1389–99." href="#ref-CR49" id="ref-link-section-d98262920e1004_1">49</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–30." href="/articles/s41375-024-02401-9#ref-CR50" id="ref-link-section-d98262920e1007">50</a>]. Combination treatment of BAK/BAX double knockout (DKO) cells did not induce apoptosis at 4 h, whilst capivasertib reduced AKT signalling (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig2">2E</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">2B</a>). Growth inhibition in BAK/BAX DKO GCB-DLBCL cell lines following combination treatment was equivalent to monotherapy capivasertib (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig3">3A</a>). Individual knockdown of either BAX or BAK did not block induction of apoptosis (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">2B</a>) suggesting cell priming death is mediated through BAX or BAK. Additionally, caspase-8 induction was attenuated in the BAK/BAX DKO GCB-DLBCL cell lines after combination treatment (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig3">3B, C</a>). These results suggest that combining capivasertib and venetoclax induces cell death by direct effects on mitochondria.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="Combination-mediated induction of cell death markers ablated by BAK/BAX codeletion in responsive DLBCL cell models."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: Combination-mediated induction of cell death markers ablated by BAK/BAX codeletion in responsive DLBCL cell models.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="1093"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>A</b> Growth inhibition of BAK/BAX WT and DKO WSU-DLCL2 and SUDHL4 cells treated as indicated in a 72-hr measured by relative Cell Titer Glo signal growth assay (<i>n</i> = 3/group; 2-way ANOVA with Sidak’s multiple comparisons of the means between WT and DKO in the same treatment group ****<i>p</i> &lt; 0.001). <b>B</b> Relative fold change of caspase-8 activity in BAK/BAX WT and DKO WSU-DLCL2 and SUDHL4 cells treated as indicated for 4 h. Staurosporine (5 µM) was a general positive control for caspase induction and cell killing. <i>n</i> = 3/group; 2-way ANOVA with Sidak’s multiple comparisons of the means between WT and DKO in the same treatment group ****<i>p</i> &lt; 0.001. <b>C</b> Western blot profile of BAK/BAX WT and DKO WSU-DLCL2 and SUDHL4 cells treated with compounds for 4 h in normal glucose-rich growth medium or with medium where glucose is substituted with galactose.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Given AKT signalling regulates metabolism and in particular glucose homeostasis, we hypothesised that metabolic stress may enhance venetoclax activity. We evaluated whether galactose substitution in media could mimic capivasertib mediated inhibition of glucose uptake. Galactose supplementation failed to modulate AKT pathway activation or inhibition of AKT signalling by capivasertib in wildtype and BAK/BAX DKO cell lines. Interestingly, in galactose-substituted medium venetoclax monotherapy treatment resulted in greater induction of cell death markers than in glucose-rich medium, but induction of cell death was not as effective as capivasertib and venetoclax (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig3">3C</a>). Moreover, cleavage of caspases -3, and -9 was enhanced by combination relative to venetoclax treatment irrespective of medium conditions (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig3">3C</a>). Again, combination treatment induced cleavage of caspase-9, -3 and -8 (a component of the death-inducing signalling complex canonically associated with the extrinsic apoptosis pathway) and was abrogated upon deletion of BAK and BAX in the presence and absence of galactose (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig3">3C</a>). Collectively, these data suggest that whilst modulation of glucose uptake and metabolic regulation by capivasertib could enhance apoptosis induction by venetoclax, other AKT dependent mechanisms are contributing to the combination effect.</p><h3 class="c-article__sub-heading" id="Sec11">Capivasertib and venetoclax are efficacious in wildtype and PTEN-null DLBCL tumour xenografts with different doses and schedules</h3><p>Next the capivasertib and venetoclax combination was validated in vivo. Clinically, capivasertib is administered using an intermittent 4-days on and 3-days off schedule and venetoclax once daily. Consideration of needing to alter dose and schedule in mice with this combination, alternative schedules to evaluate efficacy in vivo was also explored. Mice bearing <i>PTEN</i>-wildtype SUDLH-4 tumour xenografts were treated with both capivasertib 130 mg/kg BID 4-days on/3-days off and venetoclax 100 mg/kg once daily 4-days on/3-days off. Both capivasertib or venetoclax monotherapy treatments gave modest inhibition of relative tumour growth (74% and 46% TGI respectively). Combination treatment gave complete tumour regression (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig4">4A</a>). Whilst concurrent dosing was highly efficacious, combination treatment on a 4-days on/3-days off schedule exhibited occasional but manageable body weight loss in mice. Therefore, considering that frequent dose alterations of venetoclax are provided clinically, exploration of different dose schedules the combination were evaluated to understand different combination regimens that maintained efficacy whilst minimising potential tolerability issues (Supp. Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM1">S4</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">3A, B</a>). Doses of both drugs varied, however the 4-days on/3-days off capivasertib schedule remained constant whilst frequency of venetoclax varied. Sequential dosing of capivasertib for 4 consecutive days followed by venetoclax for 3 consecutive days reduced combination benefit showing concurrent drug administration drives optimal efficacy (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig4">4B</a>). Reducing either the dosing frequency or dose level of venetoclax whilst maintaining the clinically relevant capivasertib treatment regimen was assessed. Reduction venetoclax from 100 to 30 mg/kg once daily 4-days on/ 3-days off concurrently with capivasertib drove tumour regressions (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig4">4C</a>). However, duration of tumour response after treatment cessation was reduced versus the full clinically relevant schedule (data not shown). Frequency reductions of venetoclax administration to 100 mg/kg once daily to day 1 or days 1 and 3 drove tumour regressions with minimal body weight loss (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig4">4A, B</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">3A</a>). However, tumour regrowth was observed 10 days after dosing cessation. Finally, reducing capivasertib to 45 mg/kg 4-days on/3-days off schedule with 100 mg/kg of venetoclax led to a loss of efficacy (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig4">4C</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">3C</a>). Collectively, this suggests that inhibition of AKT is sufficient in priming the combination response, however the induction of cell death can still be achieved with various dose levels of both compounds and frequency of venetoclax treatment.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="Combination of capivasertib with venetoclax induces sustained tumour regression in a PTEN-wildtype SUDHL4 xenograft model."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: Combination of capivasertib with venetoclax induces sustained tumour regression in a PTEN-wildtype SUDHL4 xenograft model.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="863"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p><b>A</b> Tumour growth curves of CB.17 SCID mice bearing the GCB-DLBCL cell line SuDHL4 xenograft tumours treated with capivasertib (130 mg/kg BID 10/14 4-day on/3-day off) monotherapy, venetoclax (100 mg/kg QD) monotherapy and in combination in accordance with schedules captured in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM1">1</a>. <b>B</b> Assessment of sustained tumour regression (&gt;60 days post dosing). Both capivasertib and venetoclax were administered on a 4-day on/3-day off schedule relative to combinations using reduced frequency of venetoclax treatment. <b>C</b> Assessment of tumour activity of capivasertib dose reduction versus venetoclax dose reduction on anti-tumour response or tumour regression. Data is represented as geometric mean of tumour volumes and standard error of the mean. *<i>p</i> &lt; 0.05, **<i>p</i> &lt; 0.001, ***<i>p</i> &lt; 0.0001.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec12">Combination treatment reduces growth of human DLBCL PDX models</h3><p>To further explore this combination in vivo, two DLBCL PDX mouse models that represent relapsed/refractory DLBCL were evaluated. A GCB PDX model, VFN-D7 DHL with low PTEN protein (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig5">5A</a>) expression harbours both a BCL2 and MYC translocation, hallmarks of double hit lymphoma and the VFN-D1 KTC PDX model has wildtype PTEN protein levels (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig5">5A</a>), a BCL2 amplification and MYC copy number gain. PDX models were derived from chemotherapy refractory DLBCL patients [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 51" title="Jaksa R, Karolova J, Svaton M, Kazantsev D, Grajciarova M, Pokorna E, et al. Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Lab Invest. 2022;102:957–65." href="/articles/s41375-024-02401-9#ref-CR51" id="ref-link-section-d98262920e1173">51</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2016;22:1138–49." href="/articles/s41375-024-02401-9#ref-CR52" id="ref-link-section-d98262920e1176">52</a>]. These PDX models are established in NSG mice and therefore to accommodate differences in tolerance amongst mouse strains, the drug combination was administered on a modified schedule of 3-days on/4-days off (Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">3D, E</a>). In both models, the capivasertib and venetoclax combination suppressed tumour growth. (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig5">5B, C</a>). Therefore, the combination can also deliver improved anti-tumour benefit in vivo in BCL2-positive chemotherapy refractory DLCBL malignancies.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-5" data-title="Combination of capivasertib with venetoclax promotes tumour regression in a PTEN-wildtype and PTEN-null DLBCL PDX mouse models."><figure><figcaption><b id="Fig5" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 5: Combination of capivasertib with venetoclax promotes tumour regression in a PTEN-wildtype and PTEN-null DLBCL PDX mouse models.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/5" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig5_HTML.png?as=webp"><img aria-describedby="Fig5" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig5_HTML.png" alt="figure 5" loading="lazy" width="685" height="309"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-5-desc"><p><b>A</b> Western blot analysis of PTEN expression in the VFN-D7 and VFN-D1_KTC human DLBCL PDX models. <b>B</b> Tumour growth curves of NSG mice bearing tumours with the double-hit GCB DLBCL PDX model, VFN-D7 or (<b>C</b>) the non-GCB DLCBL PTEN deficient PDX model, VFN-D1_KTC treated with capivasertib on a slightly modified schedule (130 mg/kg BID 10/14 3-day on/4-day off) monotherapy, venetoclax (100 mg/kg QD) and in combination with both agents on 3-day on/4-day off schedule. Comparison of combination treatment tumour regression compared to either monotherapy groups. Data is represented as arithmetic mean and standard error of the mean. *<i>p</i> &lt; 0.05, **<i>p</i> &lt; 0.001, ***<i>p</i> &lt; 0.0001.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/5" data-track-dest="link:Figure5 Full size image" aria-label="Full size image figure 5" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec13">AKT and BCL-2 inhibition combines with CD20 antagonism and overcomes RCHOP resistance</h3><p>Next, we evaluated whether antagonising CD20 using rituximab could further the enhance combination response in PTEN-wildtype SUDHL4, PTEN low protein SUDHL5, and <i>PTEN</i>-null WSU-DLCL2 xenograft models. The triple regimen consisted of capivasertib on 4-day/3-day off schedule, venetoclax given twice weekly and rituximab given twice weekly. In the SUDHL4 xenograft model, the triple combination of capivasertib, venetoclax and rituximab achieved superior efficacy relative to monotherapy and combination arms (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig6">6A</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">3F</a>). Similarly, superior, continuous efficacy was observed in the SUDHL5 xenograft model after a single week following the triple drug regimen exemplifying the anti-tumoral response of this combination (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig6">6B</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">3G</a>). In WSU-DLCL2 xenograft model, the triple regimen resulted in long-term durable responses relative to the combination capivasertib and venetoclax (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig6">6C, D</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">3H</a>). Lastly, given that most DLBCL patients receive RCHOP therapy, we sought to determine whether the triple regimen has potential to be remain active in tumours progressing on RCHOP therapy. Mice bearing WSU-DLCL2 tumours were treated with RCHOP then during tumour progression, mice received the triple regimen which led to rapid tumour regression with kinetics similar to RCHOP naïve DLBCL tumour xenograft models (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41375-024-02401-9#Fig6">6E</a>, Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM2">3J</a>). Collectively, these data suggests that treatment with capivasertib and venetoclax can be further enhanced with anti-CD20 treatment and can be therapeutic in RCHOP resistant setting of DLBCL.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-6" data-title="Combination of capivasertib, venetoclax and rituximab promotes tumour regression in GCB-DLBCL cell line xenograft models and in a RHCOP resistant DLBCL xenograft model."><figure><figcaption><b id="Fig6" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 6: Combination of capivasertib, venetoclax and rituximab promotes tumour regression in GCB-DLBCL cell line xenograft models and in a RHCOP resistant DLBCL xenograft model.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/6" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig6_HTML.png?as=webp"><img aria-describedby="Fig6" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_Fig6_HTML.png" alt="figure 6" loading="lazy" width="685" height="807"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-6-desc"><p>Assessment of tumour regressions following addition of once weekly rituximab to capivasertib and venetoclax relative to the capivasertib and venetoclax combination on 4-day on/3-day off schedule. <b>A</b>, <b>B</b> Tumour growth curves of CB.17 SCID mice bearing with the GCB-DLBCL cell line (<b>A</b>) SUDHL4 and (<b>B</b>) SUDHL5 xenograft models treated with capivasertib (130 mg/kg BID 10/14 4-day on/3-day off) monotherapy, venetoclax (100 mg/kg QD) monotherapy or rituximab (10 mg/kg 2QW) monotherapy and in combination in accordance with schedules shown in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM1">1</a>. <b>C</b> Comparison of initial tumour response and tumour regression following the triple combination of capivasertib, venetoclax and rituximab in the WSU-DLCL2 xenograft model relative to the doublet combinations and RCHOP (10 mg/kg rituximab 2QW, 25 mg/kg cyclophosphamide once IP, 3 mg/kg doxorubicin hydrochloride once IV, 0.25 mg/kg vincristine sulphate once IV and 0.5 mg/kg prednisone QD5 PO) treated as indicated (see Supp. Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41375-024-02401-9#MOESM1">S4</a>). <b>D</b> Assessment of the sustained tumour regressions in the capivasertib venetoclax versus capivasertib venetoclax rituximab groups. <b>E</b> Tumours from the RCHOP treated group shown in (<b>C</b>) that were resistant to treatment (purple dots) were retreated with the capivasertib, venetoclax and rituximab triplet (yellow dots) and tumour regression assessed. All data is represented as geometric mean of tumour volumes and standard error of the mean (*<i>p</i> &lt; 0.05, **<i>p</i> &lt; 0.001, ***<i>p</i> &lt; 0.0001).</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41375-024-02401-9/figures/6" data-track-dest="link:Figure6 Full size image" aria-label="Full size image figure 6" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec14-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec14">Discussion</h2><div class="c-article-section__content" id="Sec14-content"><p>Here we show for the first time that combination of capivasertib and venetoclax has potential to provide broad activity in PTEN-wildtype and PTEN-deficient DLBCL preclinical models. This combination causes death of DLBCL cell lines in vitro and is highly efficacious in various lymphoma models in vivo. Concurrent dosing of capivasertib and venetoclax is necessary for optimal anti-tumoral activity and more importantly, we found that combination efficacy and disease control persists following adjustments to either dose level or frequency of venetoclax. Although reducing frequency of venetoclax treatment slightly reduced overall disease control in certain models, addition of rituximab restored maximal efficacy and promoted durable tumour regressions. Whilst directly targeting PI3K demonstrates clinical efficacy in haematological disorders, long-term treatment leads to toxicity issues thereby limiting therapeutic benefit [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, et al. Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ Breast Cancer. 2023;9:64." href="/articles/s41375-024-02401-9#ref-CR53" id="ref-link-section-d98262920e1330">53</a>]. AKT inhibitors offer an alternative approach to target downstream of PI3K, thus bypassing clinical tolerability issues, particularly in drug combination settings.</p><p>The PI3K-AKT pathway provides differential growth signals in DLBCL, however different subsets of disease are impacted by targeting different nodes in the pathway [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22." href="/articles/s41375-024-02401-9#ref-CR7" id="ref-link-section-d98262920e1336">7</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, et al. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. 2016;7:9163–74." href="/articles/s41375-024-02401-9#ref-CR13" id="ref-link-section-d98262920e1339">13</a>]. Monotherapy treatment with PI3Kα/δ inhibitors reduces growth of ABC-DLBCL cell lines and tumour models, whilst monotherapy AKT inhibition in effective in PTEN null GCB DLBCL [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22." href="/articles/s41375-024-02401-9#ref-CR7" id="ref-link-section-d98262920e1342">7</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23:826–38." href="/articles/s41375-024-02401-9#ref-CR9" id="ref-link-section-d98262920e1345">9</a>]. Comprehensive inhibition of PI3K-AKT-mTOR signalling with the combination of mTORC1/2 and PI3Kβ inhibitors is effective in DLBCL cell lines of different subtypes [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Pongas GN, Annunziata CM, Staudt LM. PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma. Oncotarget. 2017;8:81794–802." href="/articles/s41375-024-02401-9#ref-CR8" id="ref-link-section-d98262920e1348">8</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178–89." href="/articles/s41375-024-02401-9#ref-CR29" id="ref-link-section-d98262920e1352">29</a>]. However, for the capivasertib venetoclax combination it was not possible to identify a specific subtype where the combination is more active, nonetheless broad anti-tumoral activity was seen in GCB-DLBCL models. PTEN protein loss is associated with GCB tumours [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Pfeifer M, Lenz G. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma. Cell Cycle. 2013;12:3347–8." href="/articles/s41375-024-02401-9#ref-CR6" id="ref-link-section-d98262920e1355">6</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22." href="/articles/s41375-024-02401-9#ref-CR7" id="ref-link-section-d98262920e1358">7</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178–89." href="/articles/s41375-024-02401-9#ref-CR29" id="ref-link-section-d98262920e1361">29</a>] however, GCB-DLBCL PTEN wildtype models are also sensitive to combination treatment. Additionally, in the few ABC-DLBCL cells lines analysed, minimal activity was observed. It is however possible that combination activity is restricted to BCL2 positive lymphomas. Additional studies are necessary to refine patient selection strategies, although the data presented here suggest GCB-DLBCL would have the best outcomes with this combination. It is worth noting, activation of AKT signalling and expression of BCL2 fails to accurately predict combination sensitivity. For example, capivasertib activity is seen in the OCI-LY7 model that has lower levels of AKT signalling. Conversely, a lack of combination response could reflect other mutational drivers, or cellular factors that antagonise venetoclax activity. It is not clear what effect the combination of capivasertib and venetoclax has on other B-cell lineages, and whether it would mimic the B-cell depleting effects of rituximab.</p><p>AKT monotherapy activity in PTEN protein deficient solid and haematological tumour cell lines is expected, as well as in tumour with activating alteration in PIK3CA and AKT1. However, capivasertib can deliver monotherapy and combination activity beyond tumours with alterations in PTEN, PIK3CA or AKT1 [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873–87." href="/articles/s41375-024-02401-9#ref-CR25" id="ref-link-section-d98262920e1367">25</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, et al. Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ Breast Cancer. 2023;9:64." href="#ref-CR53" id="ref-link-section-d98262920e1370">53</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Eberlein C, Williamson SC, Hopcroft L, Ros S, Moss JI, Kerr J, et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br J Cancer. 2024;130:1377–87." href="#ref-CR54" id="ref-link-section-d98262920e1370_1">54</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55" title="Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, et al. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget. 2016;7:22128–39." href="/articles/s41375-024-02401-9#ref-CR55" id="ref-link-section-d98262920e1373">55</a>]. This is consistent with PI3K signalling regulating cell cycle and proliferation, AKT regulation of apoptosis, cholesterol biosynthesis, glucose metabolism, and gene expression [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70–80." href="#ref-CR56" id="ref-link-section-d98262920e1376">56</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, et al. Inhibiting PI3Kbeta with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clin Cancer Res. 2017;23:7584–95." href="#ref-CR57" id="ref-link-section-d98262920e1376_1">57</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, et al. Combined Inhibition of PI3Kbeta and mTOR Inhibits Growth of PTEN-null Tumors. Mol Cancer Ther. 2018;17:2309–19." href="#ref-CR58" id="ref-link-section-d98262920e1376_2">58</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer. Int J Biol Sci. 2024;20:3113–25." href="/articles/s41375-024-02401-9#ref-CR59" id="ref-link-section-d98262920e1379">59</a>]. This heterogeneity in dependency on different PI3K-AKT-mTOR signalling nodes in DLBCL suggests whilst the PI3K-AKT signalling pathway is critically important, the mechanism may vary between cell lines [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22." href="/articles/s41375-024-02401-9#ref-CR7" id="ref-link-section-d98262920e1383">7</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178–89." href="/articles/s41375-024-02401-9#ref-CR29" id="ref-link-section-d98262920e1386">29</a>].</p><p>Mechanistic studies in cell lines suggest that the combination drives cell death primarily through the intrinsic apoptotic pathway via MOMP formation, which engages caspase-8 and commonly initiates the extrinsic apoptosis pathway. This is accomplished without any intrinsic crosstalk between AKT signalling and intrinsic apoptosis pathways. A similar effect is observed in PTEN null breast cancer cell lines where AKT inhibition combines with the MCL-1 inhibitor AZD5991 to increase cell death independent of upstream PI3K pathway regulation [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene. 2022;41:5046–60." href="/articles/s41375-024-02401-9#ref-CR60" id="ref-link-section-d98262920e1392">60</a>]. Targeting PI3K, AKT or mTORC2 has been a proposed strategy to sensitize malignancies to BH3-mimetics [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593." href="/articles/s41375-024-02401-9#ref-CR20" id="ref-link-section-d98262920e1395">20</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011;71:5204–13." href="/articles/s41375-024-02401-9#ref-CR22" id="ref-link-section-d98262920e1398">22</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70–80." href="/articles/s41375-024-02401-9#ref-CR56" id="ref-link-section-d98262920e1401">56</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, et al. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7:e565." href="#ref-CR61" id="ref-link-section-d98262920e1404">61</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018;24:3967–80." href="#ref-CR62" id="ref-link-section-d98262920e1404_1">62</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Scott Lee J, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/ mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202–17." href="#ref-CR63" id="ref-link-section-d98262920e1404_2">63</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 64" title="Spender LC, Inman GJ. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt’s lymphoma cells to BH3 mimetics. Mol Cancer Res. 2012;10:347–59." href="/articles/s41375-024-02401-9#ref-CR64" id="ref-link-section-d98262920e1408">64</a>]. That capivasertib and venetoclax activity can be partially replicated with venetoclax monotherapy in galactose-substituted culture medium suggests that in part AKT inhibition may prime apoptosis through regulation of cellular metabolism. However, this does not wholly explain the combination response as venetoclax treatment in galactose-supplemented medium did not result in comparable changes in apoptotic caspase activity implying simply modulating glucose uptake is not sufficient to replicate the combination activity of capivasertib and venetoclax. Capivasertib monotherapy led to modest Mcl-1 degradation which was more evident in the combination with venetoclax. Again, this was not apparent following galactose supplementation. This may imply that AKT activity has some effect on or regulates Mcl-1 stability although the change in MCL-1 protein levels was modest and variable [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011;71:5204–13." href="/articles/s41375-024-02401-9#ref-CR22" id="ref-link-section-d98262920e1411">22</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63" title="Scott Lee J, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/ mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202–17." href="/articles/s41375-024-02401-9#ref-CR63" id="ref-link-section-d98262920e1414">63</a>]. However, we did not observe general regulation of BAD or BIM proteins or other regulators apoptosis. It is possible that modest reduction of Mcl-1 expression along with Bcl-2 inhibition may contribute to enhanced killing capacity by the combination and reduce a potential resistance mechanism [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 2005;280:10491–10500." href="/articles/s41375-024-02401-9#ref-CR43" id="ref-link-section-d98262920e1417">43</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 65" title="Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368." href="/articles/s41375-024-02401-9#ref-CR65" id="ref-link-section-d98262920e1420">65</a>, <a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66" title="Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341." href="/articles/s41375-024-02401-9#ref-CR66" id="ref-link-section-d98262920e1423">66</a>].</p><p>Combining the PI3Kα/δ copanlisib and venetoclax has activity in haematological cancers, AML, MCL and DLBCL, however the mechanistic drivers of anti-tumoral activity remains elusive [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23:826–38." href="/articles/s41375-024-02401-9#ref-CR9" id="ref-link-section-d98262920e1430">9</a>]. In AML cells combining the AKT inhibitor ipatasertib (GDC-0068) with venetoclax [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, et al. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Res. 2018;78:3075–86." href="/articles/s41375-024-02401-9#ref-CR67" id="ref-link-section-d98262920e1433">67</a>], resulted in cell death through BAX, with BAX deletion preventing cell death. This is possibly through direct phosphorylation of BAX by AKT [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 68" title="Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, et al. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 2018;19:e45235." href="/articles/s41375-024-02401-9#ref-CR68" id="ref-link-section-d98262920e1436">68</a>] increasing association with the mitochondria, however in our study deleting BAX had minimal effect on combination sensitivity. Ipatasertib can induce apoptosis in cell lines through PUMA regulation however no evidence of an effect on PUMA in PTEN deficient tumour cells (data not shown) [<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 69" title="Sun L, Huang Y, Liu Y, Zhao Y, He X, Zhang L, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell death Dis. 2018;9:911." href="/articles/s41375-024-02401-9#ref-CR69" id="ref-link-section-d98262920e1439">69</a>]. Interestingly, in PTEN deficient breast lines, synergy between the PI3Kβ inhibitor AZD8186 or capivasertib and AZD5991 (Mcl-1 inhibitor) depends on BAK and is differentiated from the effects in other studies and may indicate that sensitivity can be modulated through both BAK and BAX depending on context, perhaps through non-canonical mechanisms of regulation. An alternate hypothesis is that AKT pathway inhibition induces mitochondrial stress, priming loading of BAK (or BAX) complexes to the mitochondrial membrane with oligomerisation and lysis then triggered by the addition of the MCL1 inhibition. Finally modest cytochrome c leakage from the mitochondria either through PI3K pathway inhibition could be augmented using the combination of capivasertib and venetoclax.</p><p>In summary, we show here that combinations of capivasertib, venetoclax and rituximab are highly active in GCB DLBCL models. The combination activity can be achieved with flexible dosing of venetoclax allows potential to modified dose and schedule clinically to manage tolerability. Given the clinical challenges associated with PI3K inhibitors in haematological disease, capivasertib represents a novel approach to target the PI3K-AKT signalling axis with a different tolerability profile. Moreover, targeting AKT has the potential to combine with other relevant targeted therapies to improve response in subsets of DLBCL. The combination of capivasertib and venetoclax with addition of a CD20 antagonist is a potential therapeutic regimen for clinical evaluation in patients with relapsed/refractory DLCBL.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>Reagents and data can be accessed as appropriate by contacting simon.t.barry@astrazeneca.com.</p>
            </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXjs1ans74%3D" aria-label="CAS reference 1">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26980727" aria-label="PubMed reference 1">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874220" aria-label="PubMed Central reference 1">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=The%202016%20revision%20of%20the%20World%20Health%20Organization%20classification%20of%20lymphoid%20neoplasms&amp;journal=Blood&amp;volume=127&amp;pages=2375-90&amp;publication_year=2016&amp;author=Swerdlow%2CSH&amp;author=Campo%2CE&amp;author=Pileri%2CSA&amp;author=Harris%2CNL&amp;author=Stein%2CH&amp;author=Siebert%2CR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020;37:551–68.e14.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXntlSis7s%3D" aria-label="CAS reference 2">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32289277" aria-label="PubMed reference 2">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8459709" aria-label="PubMed Central reference 2">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20Probabilistic%20Classification%20Tool%20for%20Genetic%20Subtypes%20of%20Diffuse%20Large%20B%20Cell%20Lymphoma%20with%20Therapeutic%20Implications&amp;journal=Cancer%20Cell&amp;volume=37&amp;pages=551-68.e14&amp;publication_year=2020&amp;author=Wright%2CGW&amp;author=Huang%2CDW&amp;author=Phelan%2CJD&amp;author=Coulibaly%2CZA&amp;author=Roulland%2CS&amp;author=Young%2CRM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Roschewski M, Phelan JD, Wilson WH. Molecular Classification and Treatment of Diffuse Large B-Cell Lymphoma and Primary Mediastinal B-Cell Lymphoma. Cancer J. 2020;26:195–205.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtVylu77N" aria-label="CAS reference 3">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32496453" aria-label="PubMed reference 3">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285963" aria-label="PubMed Central reference 3">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Molecular%20Classification%20and%20Treatment%20of%20Diffuse%20Large%20B-Cell%20Lymphoma%20and%20Primary%20Mediastinal%20B-Cell%20Lymphoma&amp;journal=Cancer%20J&amp;volume=26&amp;pages=195-205&amp;publication_year=2020&amp;author=Roschewski%2CM&amp;author=Phelan%2CJD&amp;author=Wilson%2CWH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N. Engl J Med. 2022;386:351–63.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XisFSks78%3D" aria-label="CAS reference 4">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34904799" aria-label="PubMed reference 4">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Polatuzumab%20Vedotin%20in%20Previously%20Untreated%20Diffuse%20Large%20B-Cell%20Lymphoma&amp;journal=N.%20Engl%20J%20Med&amp;volume=386&amp;pages=351-63&amp;publication_year=2022&amp;author=Tilly%2CH&amp;author=Morschhauser%2CF&amp;author=Sehn%2CLH&amp;author=Friedberg%2CJW&amp;author=Trneny%2CM&amp;author=Sharman%2CJP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Wang J, Xu-Monette ZY, Jabbar KJ, Shen Q, Manyam GC, Tzankov A, et al. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol. 2017;187:1700–16.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtVWrtrnE" aria-label="CAS reference 5">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28627414" aria-label="PubMed reference 5">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530910" aria-label="PubMed Central reference 5">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=AKT%20Hyperactivation%20and%20the%20Potential%20of%20AKT-Targeted%20Therapy%20in%20Diffuse%20Large%20B-Cell%20Lymphoma&amp;journal=Am%20J%20Pathol&amp;volume=187&amp;pages=1700-16&amp;publication_year=2017&amp;author=Wang%2CJ&amp;author=Xu-Monette%2CZY&amp;author=Jabbar%2CKJ&amp;author=Shen%2CQ&amp;author=Manyam%2CGC&amp;author=Tzankov%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Pfeifer M, Lenz G. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma. Cell Cycle. 2013;12:3347–8.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXhs1Wltbc%3D" aria-label="CAS reference 6">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24091535" aria-label="PubMed reference 6">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895419" aria-label="PubMed Central reference 6">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=PI3K%2FAKT%20addiction%20in%20subsets%20of%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Cell%20Cycle&amp;volume=12&amp;pages=3347-8&amp;publication_year=2013&amp;author=Pfeifer%2CM&amp;author=Lenz%2CG">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, et al. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. Blood. 2017;130:310–22.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhs1aqsrbF" aria-label="CAS reference 7">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28202458" aria-label="PubMed reference 7">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Sensitivity%20to%20PI3K%20and%20AKT%20inhibitors%20is%20mediated%20by%20divergent%20molecular%20mechanisms%20in%20subtypes%20of%20DLBCL&amp;journal=Blood&amp;volume=130&amp;pages=310-22&amp;publication_year=2017&amp;author=Erdmann%2CT&amp;author=Klener%2CP&amp;author=Lynch%2CJT&amp;author=Grau%2CM&amp;author=Vo%C4%8Dkov%C3%A1%2CP&amp;author=Molinsky%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Pongas GN, Annunziata CM, Staudt LM. PI3Kδ inhibition causes feedback activation of PI3Kα in the ABC subtype of diffuse large B-cell lymphoma. Oncotarget. 2017;8:81794–802.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29137222" aria-label="PubMed reference 8">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669848" aria-label="PubMed Central reference 8">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=PI3K%CE%B4%20inhibition%20causes%20feedback%20activation%20of%20PI3K%CE%B1%20in%20the%20ABC%20subtype%20of%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Oncotarget&amp;volume=8&amp;pages=81794-802&amp;publication_year=2017&amp;author=Pongas%2CGN&amp;author=Annunziata%2CCM&amp;author=Staudt%2CLM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013;23:826–38.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXptFKks7w%3D" aria-label="CAS reference 9">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23764004" aria-label="PubMed reference 9">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3700321" aria-label="PubMed Central reference 9">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=SYK%20inhibition%20modulates%20distinct%20PI3K%2FAKT-%20dependent%20survival%20pathways%20and%20cholesterol%20biosynthesis%20in%20diffuse%20large%20B%20cell%20lymphomas&amp;journal=Cancer%20Cell&amp;volume=23&amp;pages=826-38&amp;publication_year=2013&amp;author=Chen%2CL&amp;author=Monti%2CS&amp;author=Juszczynski%2CP&amp;author=Ouyang%2CJ&amp;author=Chapuy%2CB&amp;author=Neuberg%2CD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–78.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC1cjgtFCqtQ%3D%3D" aria-label="CAS reference 10">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28633365" aria-label="PubMed reference 10">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834070" aria-label="PubMed Central reference 10">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20II%20study%20of%20copanlisib%2C%20a%20PI3K%20inhibitor%2C%20in%20relapsed%20or%20refractory%2C%20indolent%20or%20aggressive%20lymphoma&amp;journal=Ann%20Oncol&amp;volume=28&amp;pages=2169-78&amp;publication_year=2017&amp;author=Dreyling%2CM&amp;author=Morschhauser%2CF&amp;author=Bouabdallah%2CK&amp;author=Bron%2CD&amp;author=Cunningham%2CD&amp;author=Assouline%2CSE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34:2184–97.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXjvVGltbg%3D" aria-label="CAS reference 11">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32060403" aria-label="PubMed reference 11">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387311" aria-label="PubMed Central reference 11">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Single-agent%20activity%20of%20phosphatidylinositol%203-kinase%20inhibition%20with%20copanlisib%20in%20patients%20with%20molecularly%20defined%20relapsed%20or%20refractory%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Leukemia&amp;volume=34&amp;pages=2184-97&amp;publication_year=2020&amp;author=Lenz%2CG&amp;author=Hawkes%2CE&amp;author=Verhoef%2CG&amp;author=Haioun%2CC&amp;author=Thye%20Lim%2CS&amp;author=Seog%20Heo%2CD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, et al. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N. Engl J Med. 2023;388:2058–70.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3sXhtFyntL%2FL" aria-label="CAS reference 12">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=37256976" aria-label="PubMed reference 12">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335038" aria-label="PubMed Central reference 12">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Capivasertib%20in%20Hormone%20Receptor-Positive%20Advanced%20Breast%20Cancer&amp;journal=N.%20Engl%20J%20Med&amp;volume=388&amp;pages=2058-70&amp;publication_year=2023&amp;author=Turner%2CNC&amp;author=Oliveira%2CM&amp;author=Howell%2CSJ&amp;author=Dalenc%2CF&amp;author=Cortes%2CJ&amp;author=Gomez%20Moreno%2CHL">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, et al. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. Oncotarget. 2016;7:9163–74.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26824321" aria-label="PubMed reference 13">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891033" aria-label="PubMed Central reference 13">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Differential%20regulation%20of%20mTOR%20signaling%20determines%20sensitivity%20to%20AKT%20inhibition%20in%20diffuse%20large%20B%20cell%20lymphoma&amp;journal=Oncotarget&amp;volume=7&amp;pages=9163-74&amp;publication_year=2016&amp;author=Ezell%2CSA&amp;author=Wang%2CS&amp;author=Bihani%2CT&amp;author=Lai%2CZ&amp;author=Grosskurth%2CSE&amp;author=Tepsuporn%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021;138:1110–9.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXitFKit7jJ" aria-label="CAS reference 14">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34320160" aria-label="PubMed reference 14">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Targeting%20B-cell%20receptor%20and%20PI3K%20signaling%20in%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Blood&amp;volume=138&amp;pages=1110-9&amp;publication_year=2021&amp;author=Xu%2CW&amp;author=Berning%2CP&amp;author=Lenz%2CG">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Cory S, Roberts AW, Colman PM, Adams JM. Targeting BCL-2-like Proteins to Kill Cancer Cells. Trends Cancer. 2016;2:443–60.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28741496" aria-label="PubMed reference 15">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Targeting%20BCL-2-like%20Proteins%20to%20Kill%20Cancer%20Cells&amp;journal=Trends%20Cancer&amp;volume=2&amp;pages=443-60&amp;publication_year=2016&amp;author=Cory%2CS&amp;author=Roberts%2CAW&amp;author=Colman%2CPM&amp;author=Adams%2CJM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N. Engl J Med. 2020;383:617–29.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhs1Slt7%2FL" aria-label="CAS reference 16">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32786187" aria-label="PubMed reference 16">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Azacitidine%20and%20Venetoclax%20in%20Previously%20Untreated%20Acute%20Myeloid%20Leukemia&amp;journal=N.%20Engl%20J%20Med&amp;volume=383&amp;pages=617-29&amp;publication_year=2020&amp;author=DiNardo%2CCD&amp;author=Jonas%2CBA&amp;author=Pullarkat%2CV&amp;author=Thirman%2CMJ&amp;author=Garcia%2CJS&amp;author=Wei%2CAH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–78.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XnslGqsbc%3D" aria-label="CAS reference 17">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27178240" aria-label="PubMed reference 17">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Venetoclax%20in%20relapsed%20or%20refractory%20chronic%20lymphocytic%20leukaemia%20with%2017p%20deletion%3A%20a%20multicentre%2C%20open-label%2C%20phase%202%20study&amp;journal=Lancet%20Oncol&amp;volume=17&amp;pages=768-78&amp;publication_year=2016&amp;author=Stilgenbauer%2CS&amp;author=Eichhorst%2CB&amp;author=Schetelig%2CJ&amp;author=Coutre%2CS&amp;author=Seymour%2CJF&amp;author=Munir%2CT">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, et al. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020;4:5226–31.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXis12ksLvM" aria-label="CAS reference 18">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33104794" aria-label="PubMed reference 18">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594393" aria-label="PubMed Central reference 18">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Combined%20EZH2%20and%20Bcl-2%20inhibitors%20as%20precision%20therapy%20for%20genetically%20defined%20DLBCL%20subtypes&amp;journal=Blood%20Adv&amp;volume=4&amp;pages=5226-31&amp;publication_year=2020&amp;author=Scholze%2CH&amp;author=Stephenson%2CRE&amp;author=Reynolds%2CR&amp;author=Shah%2CS&amp;author=Puri%2CR&amp;author=Butler%2CSD">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137:600–9.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXjvVemsbY%3D" aria-label="CAS reference 19">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33538797" aria-label="PubMed reference 19">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869186" aria-label="PubMed Central reference 19">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%202%20study%20of%20venetoclax%20plus%20R-CHOP%20as%20first-line%20treatment%20for%20patients%20with%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Blood&amp;volume=137&amp;pages=600-9&amp;publication_year=2021&amp;author=Morschhauser%2CF&amp;author=Feugier%2CP&amp;author=Flinn%2CIW&amp;author=Gasiorowski%2CR&amp;author=Greil%2CR&amp;author=Illes%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Choudhary GS, Al-Harbi S, Mazumder S, Hill BT, Smith MR, Bodo J, et al. MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies. Cell Death Dis. 2015;6:e1593.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtFOitbY%3D" aria-label="CAS reference 20">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25590803" aria-label="PubMed reference 20">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669737" aria-label="PubMed Central reference 20">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=MCL-1%20and%20BCL-xL-dependent%20resistance%20to%20the%20BCL-2%20inhibitor%20ABT-199%20can%20be%20overcome%20by%20preventing%20PI3K%2FAKT%2FmTOR%20activation%20in%20lymphoid%20malignancies&amp;journal=Cell%20Death%20Dis&amp;volume=6&amp;publication_year=2015&amp;author=Choudhary%2CGS&amp;author=Al-Harbi%2CS&amp;author=Mazumder%2CS&amp;author=Hill%2CBT&amp;author=Smith%2CMR&amp;author=Bodo%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008;7:3265–74.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXht1ensb%2FO" aria-label="CAS reference 21">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18852130" aria-label="PubMed reference 21">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=ABT-263%20and%20rapamycin%20act%20cooperatively%20to%20kill%20lymphoma%20cells%20in%20vitro%20and%20in%20vivo&amp;journal=Mol%20Cancer%20Ther&amp;volume=7&amp;pages=3265-74&amp;publication_year=2008&amp;author=Ackler%2CS&amp;author=Xiao%2CY&amp;author=Mitten%2CMJ&amp;author=Foster%2CK&amp;author=Oleksijew%2CA&amp;author=Refici%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR, et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res. 2011;71:5204–13.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXpsVOhu7w%3D" aria-label="CAS reference 22">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21670080" aria-label="PubMed reference 22">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3148426" aria-label="PubMed Central reference 22">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Akt-dependent%20glucose%20metabolism%20promotes%20Mcl-1%20synthesis%20to%20maintain%20cell%20survival%20and%20resistance%20to%20Bcl-2%20inhibition&amp;journal=Cancer%20Res&amp;volume=71&amp;pages=5204-13&amp;publication_year=2011&amp;author=Coloff%2CJL&amp;author=Macintyre%2CAN&amp;author=Nichols%2CAG&amp;author=Liu%2CT&amp;author=Gallo%2CCA&amp;author=Plas%2CDR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202–17.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26460954" aria-label="PubMed reference 23">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742099" aria-label="PubMed Central reference 23">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=MCL-1-independent%20mechanisms%20of%20synergy%20between%20dual%20PI3K%2FmTOR%20and%20BCL-2%20inhibition%20in%20diffuse%20large%20B%20cell%20lymphoma&amp;journal=Oncotarget&amp;volume=6&amp;pages=35202-17&amp;publication_year=2015&amp;author=Lee%2CJS&amp;author=Tang%2CSS&amp;author=Ortiz%2CV&amp;author=Vo%2CTT&amp;author=Fruman%2CDA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Davies AJ. Precision Medicine in DLBCL: Are We There Yet? J Clin Oncol. 2021;39:1314–6.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33621123" aria-label="PubMed reference 24">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Precision%20Medicine%20in%20DLBCL%3A%20Are%20We%20There%20Yet%3F&amp;journal=J%20Clin%20Oncol&amp;volume=39&amp;pages=1314-6&amp;publication_year=2021&amp;author=Davies%2CAJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther. 2012;11:873–87.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38Xltl2ntbs%3D" aria-label="CAS reference 25">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22294718" aria-label="PubMed reference 25">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Preclinical%20pharmacology%20of%20AZD5363%2C%20an%20inhibitor%20of%20AKT%3A%20pharmacodynamics%2C%20antitumor%20activity%2C%20and%20correlation%20of%20monotherapy%20activity%20with%20genetic%20background&amp;journal=Mol%20Cancer%20Ther&amp;volume=11&amp;pages=873-87&amp;publication_year=2012&amp;author=Davies%2CBR&amp;author=Greenwood%2CH&amp;author=Dudley%2CP&amp;author=Crafter%2CC&amp;author=Yu%2CDH&amp;author=Zhang%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202–8.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXjslagtQ%3D%3D" aria-label="CAS reference 26">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23291630" aria-label="PubMed reference 26">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=ABT-199%2C%20a%20potent%20and%20selective%20BCL-2%20inhibitor%2C%20achieves%20antitumor%20activity%20while%20sparing%20platelets&amp;journal=Nat%20Med&amp;volume=19&amp;pages=202-8&amp;publication_year=2013&amp;author=Souers%2CAJ&amp;author=Leverson%2CJD&amp;author=Boghaert%2CER&amp;author=Ackler%2CSL&amp;author=Catron%2CND&amp;author=Chen%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–95.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK2sXmtVOqsL0%3D" aria-label="CAS reference 27">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9310469" aria-label="PubMed reference 27">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=IDEC-C2B8%20%28Rituximab%29%20anti-CD20%20monoclonal%20antibody%20therapy%20in%20patients%20with%20relapsed%20low-grade%20non-Hodgkin%E2%80%99s%20lymphoma&amp;journal=Blood&amp;volume=90&amp;pages=2188-95&amp;publication_year=1997&amp;author=Maloney%2CDG&amp;author=Grillo-Lopez%2CAJ&amp;author=White%2CCA&amp;author=Bodkin%2CD&amp;author=Schilder%2CRJ&amp;author=Neidhart%2CJA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, et al. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. Int J Oncol. 2015;47:446–54.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXmvVOgsg%3D%3D" aria-label="CAS reference 28">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26095475" aria-label="PubMed reference 28">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501645" aria-label="PubMed Central reference 28">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=Combining%20AZD8931%2C%20a%20novel%20EGFR%2FHER2%2FHER3%20signalling%20inhibitor%2C%20with%20AZD5363%20limits%20AKT%20inhibitor%20induced%20feedback%20and%20enhances%20antitumour%20efficacy%20in%20HER2-amplified%20breast%20cancer%20models&amp;journal=Int%20J%20Oncol&amp;volume=47&amp;pages=446-54&amp;publication_year=2015&amp;author=Crafter%2CC&amp;author=Vincent%2CJP&amp;author=Tang%2CE&amp;author=Dudley%2CP&amp;author=James%2CNH&amp;author=Klinowska%2CT">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Xu W, Berning P, Erdmann T, Grau M, Bettazova N, Zapukhlyak M, et al. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kbeta/delta blockage in diffuse large B-cell lymphoma. Leukemia. 2023;37:178–89.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XivVCks7jN" aria-label="CAS reference 29">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36352190" aria-label="PubMed reference 29">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=mTOR%20inhibition%20amplifies%20the%20anti-lymphoma%20effect%20of%20PI3Kbeta%2Fdelta%20blockage%20in%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Leukemia&amp;volume=37&amp;pages=178-89&amp;publication_year=2023&amp;author=Xu%2CW&amp;author=Berning%2CP&amp;author=Erdmann%2CT&amp;author=Grau%2CM&amp;author=Bettazova%2CN&amp;author=Zapukhlyak%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. J Pharm Pharmacother. 2010;1:94–99.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Improving%20bioscience%20research%20reporting%3A%20The%20ARRIVE%20guidelines%20for%20reporting%20animal%20research&amp;journal=J%20Pharm%20Pharmacother&amp;volume=1&amp;pages=94-99&amp;publication_year=2010&amp;author=Kilkenny%2CC&amp;author=Browne%2CWJ&amp;author=Cuthill%2CIC&amp;author=Emerson%2CM&amp;author=Altman%2CDG">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999;96:857–68.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK1MXitFGgsr0%3D" aria-label="CAS reference 31">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10102273" aria-label="PubMed reference 31">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Akt%20promotes%20cell%20survival%20by%20phosphorylating%20and%20inhibiting%20a%20forkhead%20transcription%20factor&amp;journal=Cell&amp;volume=96&amp;pages=857-68&amp;publication_year=1999&amp;author=Brunet%2CA&amp;author=Bonni%2CA&amp;author=Zigmond%2CMJ&amp;author=Lin%2CMZ&amp;author=Juo%2CP&amp;author=Hu%2CLS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Cross DAE, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–9.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK28XltFWj" aria-label="CAS reference 32">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8524413" aria-label="PubMed reference 32">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Inhibition%20of%20glycogen%20synthase%20kinase-3%20by%20insulin%20mediated%20by%20protein%20kinase%20B&amp;journal=Nature&amp;volume=378&amp;pages=785-9&amp;publication_year=1995&amp;author=Cross%2CDAE&amp;author=Alessi%2CDR&amp;author=Cohen%2CP&amp;author=Andjelkovich%2CM&amp;author=Hemmings%2CBA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, et al. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278:10189–94.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD3sXitVCktbg%3D" aria-label="CAS reference 33">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12524439" aria-label="PubMed reference 33">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Identification%20of%20a%20proline-rich%20Akt%20substrate%20as%20a%2014-3-3%20binding%20partner&amp;journal=J%20Biol%20Chem&amp;volume=278&amp;pages=10189-94&amp;publication_year=2003&amp;author=Kovacina%2CKS&amp;author=Park%2CGY&amp;author=Bae%2CSS&amp;author=Guzzetta%2CAW&amp;author=Schaefer%2CE&amp;author=Birnbaum%2CMJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Rena G, Guo S, Cichy SC, Unterman TG, Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999;274:17179–83.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK1MXjvVGku7o%3D" aria-label="CAS reference 34">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=10358075" aria-label="PubMed reference 34">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=Phosphorylation%20of%20the%20transcription%20factor%20forkhead%20family%20member%20FKHR%20by%20protein%20kinase%20B&amp;journal=J%20Biol%20Chem&amp;volume=274&amp;pages=17179-83&amp;publication_year=1999&amp;author=Rena%2CG&amp;author=Guo%2CS&amp;author=Cichy%2CSC&amp;author=Unterman%2CTG&amp;author=Cohen%2CP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15:6541–51.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK2sXht1Oqs7o%3D" aria-label="CAS reference 35">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=8978681" aria-label="PubMed reference 35">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC452479" aria-label="PubMed Central reference 35">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Mechanism%20of%20activation%20of%20protein%20kinase%20B%20by%20insulin%20and%20IGF-1&amp;journal=EMBO%20J&amp;volume=15&amp;pages=6541-51&amp;publication_year=1996&amp;author=Alessi%2CDR&amp;author=Andjelkovic%2CM&amp;author=Caudwell%2CB&amp;author=Cron%2CP&amp;author=Morrice%2CN&amp;author=Cohen%2CP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol. 1997;7:261–9.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK2sXjsFOjtb8%3D" aria-label="CAS reference 36">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9094314" aria-label="PubMed reference 36">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=Characterization%20of%20a%203-phosphoinositide-dependent%20protein%20kinase%20which%20phosphorylates%20and%20activates%20protein%20kinase%20B%CE%B1&amp;journal=Curr%20Biol&amp;volume=7&amp;pages=261-9&amp;publication_year=1997&amp;author=Alessi%2CDR&amp;author=James%2CSR&amp;author=Downes%2CCP&amp;author=Holmes%2CAB&amp;author=Gaffney%2CPRJ&amp;author=Reese%2CCB">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem. 2005;280:40406–16.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXht1OqtrjP" aria-label="CAS reference 37">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16221682" aria-label="PubMed reference 37">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=mTOR.RICTOR%20is%20the%20Ser473%20kinase%20for%20Akt%2Fprotein%20kinase%20B%20in%203T3-L1%20adipocytes&amp;journal=J%20Biol%20Chem&amp;volume=280&amp;pages=40406-16&amp;publication_year=2005&amp;author=Hresko%2CRC&amp;author=Mueckler%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–37.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD28XhtFSitr%2FE" aria-label="CAS reference 38">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16962653" aria-label="PubMed reference 38">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=SIN1%2FMIP1%20maintains%20rictor-mTOR%20complex%20integrity%20and%20regulates%20Akt%20phosphorylation%20and%20substrate%20specificity&amp;journal=Cell&amp;volume=127&amp;pages=125-37&amp;publication_year=2006&amp;author=Jacinto%2CE&amp;author=Facchinetti%2CV&amp;author=Liu%2CD&amp;author=Soto%2CN&amp;author=Wei%2CS&amp;author=Jung%2CSY">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtlSrtbY%3D" aria-label="CAS reference 39">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15718470" aria-label="PubMed reference 39">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Phosphorylation%20and%20regulation%20of%20Akt%2FPKB%20by%20the%20rictor-mTOR%20complex&amp;journal=Science&amp;volume=307&amp;pages=1098-101&amp;publication_year=2005&amp;author=Sarbassov%2CDD&amp;author=Guertin%2CDA&amp;author=Ali%2CSM&amp;author=Sabatini%2CDM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Scheid MP, Marignani PA, Woodgett JR. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B. Mol Cell Biol. 2002;22:6247–60.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD38Xmt1entL8%3D" aria-label="CAS reference 40">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=12167717" aria-label="PubMed reference 40">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC134003" aria-label="PubMed Central reference 40">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Multiple%20phosphoinositide%203-kinase-dependent%20steps%20in%20activation%20of%20protein%20kinase%20B&amp;journal=Mol%20Cell%20Biol&amp;volume=22&amp;pages=6247-60&amp;publication_year=2002&amp;author=Scheid%2CMP&amp;author=Marignani%2CPA&amp;author=Woodgett%2CJR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5- trisphosphate-dependent activation of protein kinase B. Science. 1998;279:710–4.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DyaK1cXovValug%3D%3D" aria-label="CAS reference 41">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=9445477" aria-label="PubMed reference 41">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Protein%20kinase%20B%20kinases%20that%20mediate%20phosphatidylinositol%203%2C4%2C5-%20trisphosphate-dependent%20activation%20of%20protein%20kinase%20B&amp;journal=Science&amp;volume=279&amp;pages=710-4&amp;publication_year=1998&amp;author=Stephens%2CL&amp;author=Anderson%2CK&amp;author=Stokoe%2CD&amp;author=Erdjument-Bromage%2CH&amp;author=Painter%2CGF&amp;author=Holmes%2CAB">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Herrant M, Jacquel A, Marchetti S, Belhacene N, Colosetti P, Luciano F, et al. Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis. Oncogene. 2004;23:7863–73.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2cXotl2kur4%3D" aria-label="CAS reference 42">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15378010" aria-label="PubMed reference 42">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Cleavage%20of%20Mcl-1%20by%20caspases%20impaired%20its%20ability%20to%20counteract%20Bim-induced%20apoptosis&amp;journal=Oncogene&amp;volume=23&amp;pages=7863-73&amp;publication_year=2004&amp;author=Herrant%2CM&amp;author=Jacquel%2CA&amp;author=Marchetti%2CS&amp;author=Belhacene%2CN&amp;author=Colosetti%2CP&amp;author=Luciano%2CF">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Weng C, Li Y, Xu D, Shi Y, Tang H. Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem. 2005;280:10491–10500.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXit1ersLw%3D" aria-label="CAS reference 43">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15637055" aria-label="PubMed reference 43">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Specific%20cleavage%20of%20Mcl-1%20by%20caspase-3%20in%20tumor%20necrosis%20factor-related%20apoptosis-inducing%20ligand%20%28TRAIL%29-induced%20apoptosis%20in%20Jurkat%20leukemia%20T%20cells&amp;journal=J%20Biol%20Chem&amp;volume=280&amp;pages=10491-10500&amp;publication_year=2005&amp;author=Weng%2CC&amp;author=Li%2CY&amp;author=Xu%2CD&amp;author=Shi%2CY&amp;author=Tang%2CH">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 2006;13:1396–402.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD28XmvFaitLo%3D" aria-label="CAS reference 44">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16710362" aria-label="PubMed reference 44">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Mitochondrial%20outer%20membrane%20permeabilization%20during%20apoptosis%3A%20the%20innocent%20bystander%20scenario&amp;journal=Cell%20Death%20Differ&amp;volume=13&amp;pages=1396-402&amp;publication_year=2006&amp;author=Chipuk%2CJE&amp;author=Bouchier-Hayes%2CL&amp;author=Green%2CDR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18:157–64.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXktlGksbs%3D" aria-label="CAS reference 45">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=18314333" aria-label="PubMed reference 45">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242477" aria-label="PubMed Central reference 45">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=How%20do%20BCL-2%20proteins%20induce%20mitochondrial%20outer%20membrane%20permeabilization%3F&amp;journal=Trends%20Cell%20Biol&amp;volume=18&amp;pages=157-64&amp;publication_year=2008&amp;author=Chipuk%2CJE&amp;author=Green%2CDR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvVahs7jI" aria-label="CAS reference 46">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29149100" aria-label="PubMed reference 46">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=BCL-2%20family%20proteins%3A%20changing%20partners%20in%20the%20dance%20towards%20death&amp;journal=Cell%20Death%20Differ&amp;volume=25&amp;pages=65-80&amp;publication_year=2018&amp;author=Kale%2CJ&amp;author=Osterlund%2CEJ&amp;author=Andrews%2CDW">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621–32.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXps1egt7w%3D" aria-label="CAS reference 47">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=20683470" aria-label="PubMed reference 47">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Mitochondria%20and%20cell%20death%3A%20outer%20membrane%20permeabilization%20and%20beyond&amp;journal=Nat%20Rev%20Mol%20Cell%20Biol&amp;volume=11&amp;pages=621-32&amp;publication_year=2010&amp;author=Tait%2CSW&amp;author=Green%2CDR">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Cost GJ, Freyvert Y, Vafiadis A, Santiago Y, Miller JC, Rebar E, et al. BAK and BAX deletion using zinc-finger nucleases yields apoptosis-resistant CHO cells. Biotechnol Bioeng. 2010;105:330–40.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1MXhs1Sru73E" aria-label="CAS reference 48">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19777580" aria-label="PubMed reference 48">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=BAK%20and%20BAX%20deletion%20using%20zinc-finger%20nucleases%20yields%20apoptosis-resistant%20CHO%20cells&amp;journal=Biotechnol%20Bioeng&amp;volume=105&amp;pages=330-40&amp;publication_year=2010&amp;author=Cost%2CGJ&amp;author=Freyvert%2CY&amp;author=Vafiadis%2CA&amp;author=Santiago%2CY&amp;author=Miller%2CJC&amp;author=Rebar%2CE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Lindsten T, Ross AJ, King A, Zong W-X, Rathmell JC, Shiels HA, et al. The Combined Functions of Proapoptotic Bcl-2 Family Members Bak and Bax Are Essential for Normal Development of Multiple Tissues. Mol Cell. 2000;6:1389–99.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD3MXlvFagsg%3D%3D" aria-label="CAS reference 49">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11163212" aria-label="PubMed reference 49">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057227" aria-label="PubMed Central reference 49">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Combined%20Functions%20of%20Proapoptotic%20Bcl-2%20Family%20Members%20Bak%20and%20Bax%20Are%20Essential%20for%20Normal%20Development%20of%20Multiple%20Tissues&amp;journal=Mol%20Cell&amp;volume=6&amp;pages=1389-99&amp;publication_year=2000&amp;author=Lindsten%2CT&amp;author=Ross%2CAJ&amp;author=King%2CA&amp;author=Zong%2CW-X&amp;author=Rathmell%2CJC&amp;author=Shiels%2CHA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–30.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD3MXjt1eltr0%3D" aria-label="CAS reference 50">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=11326099" aria-label="PubMed reference 50">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049805" aria-label="PubMed Central reference 50">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Proapoptotic%20BAX%20and%20BAK%3A%20A%20requisite%20gateway%20to%20mitochondrial%20dysfunction%20and%20death&amp;journal=Science&amp;volume=292&amp;pages=727-30&amp;publication_year=2001&amp;author=Wei%2CMC&amp;author=Zong%2CWX&amp;author=Cheng%2CEHY&amp;author=Lindsten%2CT&amp;author=Panoutsakopoulou%2CV&amp;author=Ross%2CAJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="51."><p class="c-article-references__text" id="ref-CR51">Jaksa R, Karolova J, Svaton M, Kazantsev D, Grajciarova M, Pokorna E, et al. Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas. Lab Invest. 2022;102:957–65.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsFSgsrbK" aria-label="CAS reference 51">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35488033" aria-label="PubMed reference 51">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420679" aria-label="PubMed Central reference 51">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=Complex%20genetic%20and%20histopathological%20study%20of%2015%20patient-derived%20xenografts%20of%20aggressive%20lymphomas&amp;journal=Lab%20Invest&amp;volume=102&amp;pages=957-65&amp;publication_year=2022&amp;author=Jaksa%2CR&amp;author=Karolova%2CJ&amp;author=Svaton%2CM&amp;author=Kazantsev%2CD&amp;author=Grajciarova%2CM&amp;author=Pokorna%2CE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="52."><p class="c-article-references__text" id="ref-CR52">Klanova M, Andera L, Brazina J, Svadlenka J, Benesova S, Soukup J, et al. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2016;22:1138–49.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XktVyktbY%3D" aria-label="CAS reference 52">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26467384" aria-label="PubMed reference 52">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Targeting%20of%20BCL2%20Family%20Proteins%20with%20ABT-199%20and%20Homoharringtonine%20Reveals%20BCL2-%20and%20MCL1-Dependent%20Subgroups%20of%20Diffuse%20Large%20B-Cell%20Lymphoma&amp;journal=Clin%20Cancer%20Res&amp;volume=22&amp;pages=1138-49&amp;publication_year=2016&amp;author=Klanova%2CM&amp;author=Andera%2CL&amp;author=Brazina%2CJ&amp;author=Svadlenka%2CJ&amp;author=Benesova%2CS&amp;author=Soukup%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="53."><p class="c-article-references__text" id="ref-CR53">Hopcroft L, Wigmore EM, Williamson SC, Ros S, Eberlein C, Moss JI, et al. Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models. NPJ Breast Cancer. 2023;9:64.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3sXhslSnsL%2FM" aria-label="CAS reference 53">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=37543694" aria-label="PubMed reference 53">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404292" aria-label="PubMed Central reference 53">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=Combining%20the%20AKT%20inhibitor%20capivasertib%20and%20SERD%20fulvestrant%20is%20effective%20in%20palbociclib-resistant%20ER%2B%20breast%20cancer%20preclinical%20models&amp;journal=NPJ%20Breast%20Cancer&amp;volume=9&amp;publication_year=2023&amp;author=Hopcroft%2CL&amp;author=Wigmore%2CEM&amp;author=Williamson%2CSC&amp;author=Ros%2CS&amp;author=Eberlein%2CC&amp;author=Moss%2CJI">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="54."><p class="c-article-references__text" id="ref-CR54">Eberlein C, Williamson SC, Hopcroft L, Ros S, Moss JI, Kerr J, et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br J Cancer. 2024;130:1377–87.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB2cXktlKgu7k%3D" aria-label="CAS reference 54">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=38396173" aria-label="PubMed reference 54">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11014923" aria-label="PubMed Central reference 54">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=Capivasertib%20combines%20with%20docetaxel%20to%20enhance%20anti-tumour%20activity%20through%20inhibition%20of%20AKT-mediated%20survival%20mechanisms%20in%20prostate%20cancer&amp;journal=Br%20J%20Cancer&amp;volume=130&amp;pages=1377-87&amp;publication_year=2024&amp;author=Eberlein%2CC&amp;author=Williamson%2CSC&amp;author=Hopcroft%2CL&amp;author=Ros%2CS&amp;author=Moss%2CJI&amp;author=Kerr%2CJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="55."><p class="c-article-references__text" id="ref-CR55">Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, et al. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. Oncotarget. 2016;7:22128–39.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26989080" aria-label="PubMed reference 55">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008349" aria-label="PubMed Central reference 55">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=Identification%20of%20differential%20PI3K%20pathway%20target%20dependencies%20in%20T-cell%20acute%20lymphoblastic%20leukemia%20through%20a%20large%20cancer%20cell%20panel%20screen&amp;journal=Oncotarget&amp;volume=7&amp;pages=22128-39&amp;publication_year=2016&amp;author=Lynch%2CJT&amp;author=McEwen%2CR&amp;author=Crafter%2CC&amp;author=McDermott%2CU&amp;author=Garnett%2CMJ&amp;author=Barry%2CST">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="56."><p class="c-article-references__text" id="ref-CR56">Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3Kalpha/delta is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70–80.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXnt1Oiurs%3D" aria-label="CAS reference 56">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30322870" aria-label="PubMed reference 56">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318426" aria-label="PubMed Central reference 56">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=Targeted%20inhibition%20of%20PI3Kalpha%2Fdelta%20is%20synergistic%20with%20BCL-2%20blockade%20in%20genetically%20defined%20subtypes%20of%20DLBCL&amp;journal=Blood&amp;volume=133&amp;pages=70-80&amp;publication_year=2019&amp;author=Bojarczuk%2CK&amp;author=Wienand%2CK&amp;author=Ryan%2CJA&amp;author=Chen%2CL&amp;author=Villalobos-Ortiz%2CM&amp;author=Mandato%2CE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="57."><p class="c-article-references__text" id="ref-CR57">Lynch JT, Polanska UM, Delpuech O, Hancox U, Trinidad AG, Michopoulos F, et al. Inhibiting PI3Kbeta with AZD8186 Regulates Key Metabolic Pathways in PTEN-Null Tumors. Clin Cancer Res. 2017;23:7584–95.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvFOgtLfP" aria-label="CAS reference 57">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28972046" aria-label="PubMed reference 57">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=Inhibiting%20PI3Kbeta%20with%20AZD8186%20Regulates%20Key%20Metabolic%20Pathways%20in%20PTEN-Null%20Tumors&amp;journal=Clin%20Cancer%20Res&amp;volume=23&amp;pages=7584-95&amp;publication_year=2017&amp;author=Lynch%2CJT&amp;author=Polanska%2CUM&amp;author=Delpuech%2CO&amp;author=Hancox%2CU&amp;author=Trinidad%2CAG&amp;author=Michopoulos%2CF">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="58."><p class="c-article-references__text" id="ref-CR58">Lynch JT, Polanska UM, Hancox U, Delpuech O, Maynard J, Trigwell C, et al. Combined Inhibition of PI3Kbeta and mTOR Inhibits Growth of PTEN-null Tumors. Mol Cancer Ther. 2018;17:2309–19.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXmtlSksr0%3D" aria-label="CAS reference 58">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30097489" aria-label="PubMed reference 58">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 58" href="http://scholar.google.com/scholar_lookup?&amp;title=Combined%20Inhibition%20of%20PI3Kbeta%20and%20mTOR%20Inhibits%20Growth%20of%20PTEN-null%20Tumors&amp;journal=Mol%20Cancer%20Ther&amp;volume=17&amp;pages=2309-19&amp;publication_year=2018&amp;author=Lynch%2CJT&amp;author=Polanska%2CUM&amp;author=Hancox%2CU&amp;author=Delpuech%2CO&amp;author=Maynard%2CJ&amp;author=Trigwell%2CC">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="59."><p class="c-article-references__text" id="ref-CR59">Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer. Int J Biol Sci. 2024;20:3113–25.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=38904014" aria-label="PubMed reference 59">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11186371" aria-label="PubMed Central reference 59">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 59" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20PI3K%2FAkt%20Pathway%20and%20Glucose%20Metabolism%3A%20A%20Dangerous%20Liaison%20in%20Cancer&amp;journal=Int%20J%20Biol%20Sci&amp;volume=20&amp;pages=3113-25&amp;publication_year=2024&amp;author=Fontana%2CF&amp;author=Giannitti%2CG&amp;author=Marchesi%2CS&amp;author=Limonta%2CP">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="60."><p class="c-article-references__text" id="ref-CR60">Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, et al. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kbeta/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. Oncogene. 2022;41:5046–60.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38Xis1ehsLbO" aria-label="CAS reference 60">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=36241868" aria-label="PubMed reference 60">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652152" aria-label="PubMed Central reference 60">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=AKT-mTORC1%20reactivation%20is%20the%20dominant%20resistance%20driver%20for%20PI3Kbeta%2FAKT%20inhibitors%20in%20PTEN-null%20breast%20cancer%20and%20can%20be%20overcome%20by%20combining%20with%20Mcl-1%20inhibitors&amp;journal=Oncogene&amp;volume=41&amp;pages=5046-60&amp;publication_year=2022&amp;author=Dunn%2CS&amp;author=Eberlein%2CC&amp;author=Yu%2CJ&amp;author=Gris-Oliver%2CA&amp;author=Ong%2CSH&amp;author=Yelland%2CU">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="61."><p class="c-article-references__text" id="ref-CR61">Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, et al. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017;7:e565.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC1cnhslSlsw%3D%3D" aria-label="CAS reference 61">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28548645" aria-label="PubMed reference 61">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518884" aria-label="PubMed Central reference 61">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 61" href="http://scholar.google.com/scholar_lookup?&amp;title=Waldenstrom%20macroglobulinemia%20cells%20devoid%20of%20BTK%28C481S%29%20or%20CXCR4%28WHIM-like%29%20mutations%20acquire%20resistance%20to%20ibrutinib%20through%20upregulation%20of%20Bcl-2%20and%20AKT%20resulting%20in%20vulnerability%20towards%20venetoclax%20or%20MK2206%20treatment&amp;journal=Blood%20Cancer%20J&amp;volume=7&amp;publication_year=2017&amp;author=Paulus%2CA&amp;author=Akhtar%2CS&amp;author=Yousaf%2CH&amp;author=Manna%2CA&amp;author=Paulus%2CSM&amp;author=Bashir%2CY">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="62."><p class="c-article-references__text" id="ref-CR62">Pham LV, Huang S, Zhang H, Zhang J, Bell T, Zhou S, et al. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas. Clin Cancer Res. 2018;24:3967–80.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXjtVahsbY%3D" aria-label="CAS reference 62">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29666304" aria-label="PubMed reference 62">PubMed</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 62" href="http://scholar.google.com/scholar_lookup?&amp;title=Strategic%20Therapeutic%20Targeting%20to%20Overcome%20Venetoclax%20Resistance%20in%20Aggressive%20B-cell%20Lymphomas&amp;journal=Clin%20Cancer%20Res&amp;volume=24&amp;pages=3967-80&amp;publication_year=2018&amp;author=Pham%2CLV&amp;author=Huang%2CS&amp;author=Zhang%2CH&amp;author=Zhang%2CJ&amp;author=Bell%2CT&amp;author=Zhou%2CS">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="63."><p class="c-article-references__text" id="ref-CR63">Scott Lee J, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/ mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6:35202–17.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26460954" aria-label="PubMed reference 63">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742099" aria-label="PubMed Central reference 63">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 63" href="http://scholar.google.com/scholar_lookup?&amp;title=MCL-1-independent%20mechanisms%20of%20synergy%20between%20dual%20PI3K%2F%20mTOR%20and%20BCL-2%20inhibition%20in%20diffuse%20large%20B%20cell%20lymphoma&amp;journal=Oncotarget&amp;volume=6&amp;pages=35202-17&amp;publication_year=2015&amp;author=Scott%20Lee%2CJ&amp;author=Tang%2CSS&amp;author=Ortiz%2CV&amp;author=Vo%2CTT&amp;author=Fruman%2CDA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="64."><p class="c-article-references__text" id="ref-CR64">Spender LC, Inman GJ. Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt’s lymphoma cells to BH3 mimetics. Mol Cancer Res. 2012;10:347–59.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XktVams78%3D" aria-label="CAS reference 64">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22241218" aria-label="PubMed reference 64">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378513" aria-label="PubMed Central reference 64">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 64" href="http://scholar.google.com/scholar_lookup?&amp;title=Phosphoinositide%203-kinase%2FAKT%2FmTORC1%2F2%20signaling%20determines%20sensitivity%20of%20Burkitt%E2%80%99s%20lymphoma%20cells%20to%20BH3%20mimetics&amp;journal=Mol%20Cancer%20Res&amp;volume=10&amp;pages=347-59&amp;publication_year=2012&amp;author=Spender%2CLC&amp;author=Inman%2CGJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="65."><p class="c-article-references__text" id="ref-CR65">Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BC28visVGrtA%3D%3D" aria-label="CAS reference 65">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26565405" aria-label="PubMed reference 65">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670945" aria-label="PubMed Central reference 65">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 65" href="http://scholar.google.com/scholar_lookup?&amp;title=Loss%20in%20MCL-1%20function%20sensitizes%20non-Hodgkin%E2%80%99s%20lymphoma%20cell%20lines%20to%20the%20BCL-2-selective%20inhibitor%20venetoclax%20%28ABT-199%29&amp;journal=Blood%20Cancer%20J&amp;volume=5&amp;publication_year=2015&amp;author=Phillips%2CDC&amp;author=Xiao%2CY&amp;author=Lam%2CLT&amp;author=Litvinovich%2CE&amp;author=Roberts-Rapp%2CL&amp;author=Souers%2CAJ">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="66."><p class="c-article-references__text" id="ref-CR66">Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:5341.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXisFersLjK" aria-label="CAS reference 66">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30559424" aria-label="PubMed reference 66">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297231" aria-label="PubMed Central reference 66">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 66" href="http://scholar.google.com/scholar_lookup?&amp;title=Discovery%20of%20Mcl-1-specific%20inhibitor%20AZD5991%20and%20preclinical%20activity%20in%20multiple%20myeloma%20and%20acute%20myeloid%20leukemia&amp;journal=Nat%20Commun&amp;volume=9&amp;publication_year=2018&amp;author=Tron%2CAE&amp;author=Belmonte%2CMA&amp;author=Adam%2CA&amp;author=Aquila%2CBM&amp;author=Boise%2CLH&amp;author=Chiarparin%2CE">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="67."><p class="c-article-references__text" id="ref-CR67">Rahmani M, Nkwocha J, Hawkins E, Pei X, Parker RE, Kmieciak M, et al. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells. Cancer Res. 2018;78:3075–86.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhtVKjsb%2FM" aria-label="CAS reference 67">CAS</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29559471" aria-label="PubMed reference 67">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984704" aria-label="PubMed Central reference 67">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 67" href="http://scholar.google.com/scholar_lookup?&amp;title=Cotargeting%20BCL-2%20and%20PI3K%20Induces%20BAX-Dependent%20Mitochondrial%20Apoptosis%20in%20AML%20Cells&amp;journal=Cancer%20Res&amp;volume=78&amp;pages=3075-86&amp;publication_year=2018&amp;author=Rahmani%2CM&amp;author=Nkwocha%2CJ&amp;author=Hawkins%2CE&amp;author=Pei%2CX&amp;author=Parker%2CRE&amp;author=Kmieciak%2CM">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="68."><p class="c-article-references__text" id="ref-CR68">Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, et al. Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 2018;19:e45235.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29987135" aria-label="PubMed reference 68">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6123645" aria-label="PubMed Central reference 68">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 68" href="http://scholar.google.com/scholar_lookup?&amp;title=Phosphorylation%20switches%20Bax%20from%20promoting%20to%20inhibiting%20apoptosis%20thereby%20increasing%20drug%20resistance&amp;journal=EMBO%20Rep&amp;volume=19&amp;publication_year=2018&amp;author=Kale%2CJ&amp;author=Kutuk%2CO&amp;author=Brito%2CGC&amp;author=Andrews%2CTS&amp;author=Leber%2CB&amp;author=Letai%2CA">
                    Google Scholar</a> 
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="69."><p class="c-article-references__text" id="ref-CR69">Sun L, Huang Y, Liu Y, Zhao Y, He X, Zhang L, et al. Ipatasertib, a novel Akt inhibitor, induces transcription factor FoxO3a and NF-κB directly regulates PUMA-dependent apoptosis. Cell death Dis. 2018;9:911.</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30185800" aria-label="PubMed reference 69">PubMed</a> 
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125489" aria-label="PubMed Central reference 69">PubMed Central</a> 
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=Ipatasertib%2C%20a%20novel%20Akt%20inhibitor%2C%20induces%20transcription%20factor%20FoxO3a%20and%20NF-%CE%BAB%20directly%20regulates%20PUMA-dependent%20apoptosis&amp;journal=Cell%20death%20Dis&amp;volume=9&amp;publication_year=2018&amp;author=Sun%2CL&amp;author=Huang%2CY&amp;author=Liu%2CY&amp;author=Zhao%2CY&amp;author=He%2CX&amp;author=Zhang%2CL">
                    Google Scholar</a> 
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41375-024-02401-9?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>We would like to thank the in vivo AST group at Gatehouse Park for support with in vivo studies. PK was funded by Ministry of Health of the Czech Republic grant AZV NU21-03-00386, all rights reserved, and National Institute for Cancer Research (EXCELES) LX22NPO5102. Capivasertib was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics (and its collaboration with the Institute of Cancer Research and Cancer Research Technology Limited).</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="na1"><p>These authors contributed equally: Brandon S. Willis, Kevin Mongeon.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Bioscience, Early Oncology, AstraZeneca, Boston, USA</p><p class="c-article-author-affiliation__authors-list">Brandon S. Willis, Kevin Mongeon, Hannah Dry, India L. Neveras, Nadezda Bryan, Meghana Pandya, Justine Roderick-Richardson, Alan Rosen, Corinne Reimer &amp; Jerome T. Mettetal</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany</p><p class="c-article-author-affiliation__authors-list">Wendan Xu, Li Yang &amp; Georg Lenz</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic</p><p class="c-article-author-affiliation__authors-list">Liliana Tuskova &amp; Pavel Klener</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Bioscience, Early Oncology, AstraZeneca, Cambridge, UK</p><p class="c-article-author-affiliation__authors-list">Simon T. Barry</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Brandon_S_-Willis-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Brandon S. Willis</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Brandon%20S.%20Willis" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Brandon%20S.%20Willis" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Brandon%20S.%20Willis%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Kevin-Mongeon-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Kevin Mongeon</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Kevin%20Mongeon" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Kevin%20Mongeon" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Kevin%20Mongeon%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Hannah-Dry-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Hannah Dry</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Hannah%20Dry" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Hannah%20Dry" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Hannah%20Dry%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-India_L_-Neveras-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">India L. Neveras</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=India%20L.%20Neveras" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=India%20L.%20Neveras" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22India%20L.%20Neveras%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Nadezda-Bryan-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Nadezda Bryan</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nadezda%20Bryan" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nadezda%20Bryan" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nadezda%20Bryan%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Meghana-Pandya-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Meghana Pandya</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Meghana%20Pandya" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Meghana%20Pandya" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Meghana%20Pandya%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Justine-Roderick_Richardson-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Justine Roderick-Richardson</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Justine%20Roderick-Richardson" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Justine%20Roderick-Richardson" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Justine%20Roderick-Richardson%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Wendan-Xu-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Wendan Xu</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Wendan%20Xu" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Wendan%20Xu" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Wendan%20Xu%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Li-Yang-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Li Yang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Li%20Yang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Li%20Yang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Li%20Yang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Alan-Rosen-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Alan Rosen</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Alan%20Rosen" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Alan%20Rosen" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Alan%20Rosen%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Corinne-Reimer-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Corinne Reimer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Corinne%20Reimer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Corinne%20Reimer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Corinne%20Reimer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Liliana-Tuskova-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Liliana Tuskova</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Liliana%20Tuskova" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Liliana%20Tuskova" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Liliana%20Tuskova%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Pavel-Klener-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Pavel Klener</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Pavel%20Klener" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Pavel%20Klener" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Pavel%20Klener%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jerome_T_-Mettetal-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Jerome T. Mettetal</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jerome%20T.%20Mettetal" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jerome%20T.%20Mettetal" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jerome%20T.%20Mettetal%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Georg-Lenz-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Georg Lenz</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Georg%20Lenz" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Georg%20Lenz" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Georg%20Lenz%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Simon_T_-Barry-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Simon T. Barry</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Simon%20T.%20Barry" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">Search author on:</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Simon%20T.%20Barry" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide"> </span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Simon%20T.%20Barry%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>B.W. wrote the paper, supervised, designed, or provided experimental interpretation. S.T.B. wrote the paper, supervised, designed, or provided experimental interpretation. K.M. wrote the paper, generated, analyzed and interpreted data. G.L. wrote the paper, supervised, designed, or provided experimental interpretation. P.K. wrote the paper, supervised, designed, or provided experimental interpretation. J.M. supervised, designed, or provided experimental interpretation. C.R. supervised, designed, or provided experimental interpretation. H.D. generated, analyzed and interpreted data. I.N. generated, analyzed and interpreted data. W.X. generated, analyzed and interpreted data. Y.L. generated, analyzed and interpreted data. N.B. generated, analyzed and interpreted data. M.P. generated, analyzed and interpreted data. J.R.R. generated, analyzed and interpreted data. A.L. generated, analyzed and interpreted data. L.T. generated, analyzed and interpreted data. All authors commented on the manuscript.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:simon.t.barry@astrazeneca.com">Simon T. Barry</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar1">Competing interests</h3>
                <p>B.W., K.M., H.D., I.N., A.R., M.P., N.B., J.R.R., C.R., J.M., and S.B. are current or former AstraZeneca employees and shareholders.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec15-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec15">Supplementary information</h2><div class="c-article-section__content" id="Sec15-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supp materials and fig. legends" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_MOESM1_ESM.docx" data-supp-info-image="">Supp Materials and Fig. Legends</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supp figures" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41375-024-02401-9/MediaObjects/41375_2024_2401_MOESM2_ESM.pdf" data-supp-info-image="">Supp Figures</a></h3></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Potent%20combination%20benefit%20of%20the%20AKT%20inhibitor%20capivasertib%20and%20the%20BCL-2%20inhibitor%20venetoclax%20in%20diffuse%20large%20B%20cell%20lymphoma&amp;author=Brandon%20S.%20Willis%20et%20al&amp;contentID=10.1038%2Fs41375-024-02401-9&amp;copyright=The%20Author%28s%29&amp;publication=0887-6924&amp;publicationDate=2024-09-16&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41375-024-02401-9" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41375-024-02401-9" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Willis, B.S., Mongeon, K., Dry, H. <i>et al.</i> Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma.
                    <i>Leukemia</i> <b>38</b>, 2663–2674 (2024). https://doi.org/10.1038/s41375-024-02401-9</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41375-024-02401-9?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2024-02-15">15 February 2024</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2024-08-28">28 August 2024</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2024-09-16">16 September 2024</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2024-12">December 2024</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41375-024-02401-9</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-none" hidden=""><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list"></div></div></div></div></div></section>
            </div>

            

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41375-024-02401-9.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external download>
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"/></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky">
            <div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections">
                <div class="u-lazy-ad-wrapper u-mt-16 u-hide" data-component-mpu>
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2"
         class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide"
         data-ad-type="right"
         data-test="right-ad"
         data-pa11y-ignore
         data-gpt
         data-gpt-unitpath="/285/leu.nature.com/article"
         data-gpt-sizes="300x250"
         data-gpt-targeting="type=article;pos=right;artid=s41375-024-02401-9;doi=10.1038/s41375-024-02401-9;techmeta=13,60,64,95;subjmeta=1541,1990,2778,308,692,699;kwrd=Haematological+cancer,Preclinical+research">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/leu.nature.com/article&amp;sz=300x250&amp;c=1694901539&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41375-024-02401-9%26doi%3D10.1038/s41375-024-02401-9%26techmeta%3D13,60,64,95%26subjmeta%3D1541,1990,2778,308,692,699%26kwrd%3DHaematological+cancer,Preclinical+research">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/leu.nature.com/article&amp;sz=300x250&amp;c=1694901539&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41375-024-02401-9%26doi%3D10.1038/s41375-024-02401-9%26techmeta%3D13,60,64,95%26subjmeta%3D1541,1990,2778,308,692,699%26kwrd%3DHaematological+cancer,Preclinical+research"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures"></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references"></div>
        </div>
    </div>
</aside>
</div>


    
        <nav class="c-header__dropdown" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/research-articles"
                                   data-track="click"
                                   data-track-action="research articles"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/reviews-and-analysis"
                                   data-track="click"
                                   data-track-action="reviews &amp; analysis"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/news-and-comment"
                                   data-track="click"
                                   data-track-action="news &amp; comment"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/current-issue"
                                   data-track="click"
                                   data-track-action="current issue"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/collections"
                                   data-track="click"
                                   data-track-action="collections"
                                   data-track-label="link"
                                   data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link"
                               href="https://twitter.com/LeukemiaJnl"
                               data-track="click"
                               data-track-action="twitter"
                               data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link"
                               href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id&#x3D;47"
                               rel="nofollow"
                               data-track="nav_sign_up_for_alerts"
                               data-track-action="Sign up for alerts"
                               data-track-external
                               data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"/></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link"
                               href="https://www.nature.com/leu.rss"
                               data-track="click"
                               data-track-action="rss feed"
                               data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
    
    
        
            <nav class="c-header__dropdown" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/journal-information"
                                   data-track="click"
                                   data-track-action="journal information"
                                   data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/open-access"
                                   data-track="click"
                                   data-track-action="open access publishing"
                                   data-track-label="link">
                                    Open access publishing
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/editors"
                                   data-track="click"
                                   data-track-action="about the editors"
                                   data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/contact"
                                   data-track="click"
                                   data-track-action="contact"
                                   data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/supplements"
                                   data-track="click"
                                   data-track-action="supplements"
                                   data-track-label="link">
                                    Supplements
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/advertising"
                                   data-track="click"
                                   data-track-action="for advertisers"
                                   data-track-label="link">
                                    For Advertisers
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/subscribe"
                                   data-track="click"
                                   data-track-action="subscribe"
                                   data-track-label="link">
                                    Subscribe
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
        

        
            <nav class="c-header__dropdown" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/authors-and-referees"
                                   data-track="click"
                                   data-track-action="for authors &amp; referees"
                                   data-track-label="link">
                                    For Authors &amp; Referees
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services"
                                   data-track="nav_language_services"
                                   data-track-context="header publish with us dropdown menu"
                                   data-track-action="manuscript author services"
                                   data-track-label="link manuscript author services"
                                   href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link"
                                   href="/leu/open-access-funding"
                                   data-test="funding-eligibility-link"
                                   data-track="click_explore_funding"
                                   data-track-context="header publish with us"
                                   data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link"
                                   href="https://mts-leu.nature.com/cgi-bin/main.plex"
                                   data-track="click_submit_manuscript"
                                   data-track-context="submit link in Nature header dropdown menu"
                                   data-track-action="submit manuscript"
                                   data-track-label="link (publish with us dropdown menu)"
                                   data-track-external
                                   data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"/></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>


<div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width" data-track-component="nature-150-split-header">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected>All journals</option>
                                    <option value="leu">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced"
               data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>

<footer class="composite-layer" itemscope itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Leukemia
                    </span>
                    (<i itemprop="alternateName">Leukemia</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1476-5551</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">0887-6924</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/npg_/company_info/index.html"
                                                  data-track="click" data-track-action="about us"
                                                  data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/npg_/press_room/press_releases.html"
                                                  data-track="click" data-track-action="press releases"
                                                  data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/"
                                                  data-track="click" data-track-action="press office"
                                                  data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home"
                                                  data-track="click" data-track-action="contact us"
                                                  data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex"
                                                  data-track="click" data-track-action="journals a-z"
                                                  data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects"
                                                  data-track="click" data-track-action="article by subject"
                                                  data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/"
                                                  data-track="click" data-track-action="protocols.io"
                                                  data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/"
                                                  data-track="click" data-track-action="nature index"
                                                  data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/authors/editorial_policies"
                                                  data-track="click" data-track-action="Nature portfolio policies"
                                                  data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/nature-research/open-access"
                                                  data-track="click" data-track-action="open access"
                                                  data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints"
                                                  data-track="click" data-track-action="reprints and permissions"
                                                  data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/authors/research-data"
                                                  data-track="click" data-track-action="data research service"
                                                  data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://authorservices.springernature.com/language-editing/"
                                                  data-track="click" data-track-action="language editing"
                                                  data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://authorservices.springernature.com/scientific-editing/"
                                                  data-track="click" data-track-action="scientific editing"
                                                  data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/"
                                                  data-track="click" data-track-action="nature masterclasses"
                                                  data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/"
                                                  data-track="click" data-track-action="research solutions"
                                                  data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/tools-services"
                                                  data-track="click" data-track-action="librarian service and tools"
                                                  data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal"
                                                  data-track="click" data-track-action="librarian portal"
                                                  data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.nature.com/openresearch/about-open-access/information-for-institutions"
                                                  data-track="click" data-track-action="open research"
                                                  data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://www.springernature.com/gp/librarians/recommend-to-your-library"
                                                  data-track="click" data-track-action="Recommend to library"
                                                  data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/product/digital-advertising/"
                                                  data-track="click" data-track-action="advertising"
                                                  data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/"
                                                  data-track="click" data-track-action="partnerships and services"
                                                  data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/media-kits/" data-track="click"
                                                  data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link"
                                                  href="https://partnerships.nature.com/product/branded-content-native-advertising/"
                                                  data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/"
                                                  data-track="click" data-track-action="nature careers"
                                                  data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com"
                                                  data-track="click" data-track-action="nature conferences"
                                                  data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica"
                                                  data-track="click" data-track-action="nature africa"
                                                  data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com"
                                                  data-track="click" data-track-action="nature china"
                                                  data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia"
                                                  data-track="click" data-track-action="nature india"
                                                  data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly"
                                                  data-track="click" data-track-action="nature Italy"
                                                  data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp"
                                                  data-track="click" data-track-action="nature japan"
                                                  data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast"
                                                  data-track="click" data-track-action="nature middle east"
                                                  data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy"
                                          data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies"
                                          data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;"
                        data-cc-action="preferences" data-track="click" data-track-action="manage cookies"
                        data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice"
                                          data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link"
                                          href="https://www.nature.com/info/accessibility-statement" data-track="click"
                                          data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions"
                                          data-track="click" data-track-action="terms and conditions"
                                          data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa"
                                          data-track="click" data-track-action="california privacy statement"
                                          data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20"/>
    </a>
    <p class="c-footer__legal" data-test="copyright">&copy; 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <?xml version="1.0" encoding="UTF-8"?><!DOCTYPE svg PUBLIC "-//W3C//DTD SVG 1.1//EN" "http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"/></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"/></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"/></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"/></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"/></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"/></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"/></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"/></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"/></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"/></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"/></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"/></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"/></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"/></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"/></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"/></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"/></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"/></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"/></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"/></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"/></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"/></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"/></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"/></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"/></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"/></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"/></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"/></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"/></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"/></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"/></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"/></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"/></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"/></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"/></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"/></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"/></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"/></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"/></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"/></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"/></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"/><clipPath id="b"><use xlink:href="#a" style="overflow:visible"/></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"/><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"/></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"/></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"/></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"/></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"/></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"/></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"/><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"/><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"/><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"/><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"/><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"/></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"/></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"/></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 22 18"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"/></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"/></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"/></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"/></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"/></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"/></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"/></symbol><symbol id="icon-orcid-logo" viewBox="0 0 40 40"><path fill-rule="evenodd" d="M12.281 10.453c.875 0 1.578-.719 1.578-1.578 0-.86-.703-1.578-1.578-1.578-.875 0-1.578.703-1.578 1.578 0 .86.703 1.578 1.578 1.578Zm-1.203 18.641h2.406V12.359h-2.406v16.735Z"/><path fill-rule="evenodd" d="M17.016 12.36h6.5c6.187 0 8.906 4.421 8.906 8.374 0 4.297-3.36 8.375-8.875 8.375h-6.531V12.36Zm6.234 14.578h-3.828V14.53h3.703c4.688 0 6.828 2.844 6.828 6.203 0 2.063-1.25 6.203-6.703 6.203Z" clip-rule="evenodd"/></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"/></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"/></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"/></symbol></svg>
</div>
</footer>







<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41375-024-02401-9&amp;format=js&amp;last_modified=2024-09-16" async></script>
</body>
</html>